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THE SECOND UKRAINIAN-SWEDISH WORKSHOP 
“TRANSLATIONAL ONCOLOGY: OLD AND NEW PARADIGMS”
The second Ukrainian-Swedish workshop “Transla-
tional Oncology: Old and New Paradigms” took place 
at the R.E. Kavetsky Institute of Experimental Pathol-
ogy, Oncology and Radiobiology National Academy 
of Sciences of Ukraine (IEPOR NASU) on May 20–21, 
2013. Karolinska Institutet (Stockholm, Sweden) was 
co-organizer of the event.
Academician Vasyl F. Chekhun, the director 
of R.E. Kavetsky IEPOR NASU, opened the conference 
with a welcoming speech. He greeted participants and 
stressed the importance of knowledge integration 
in field of cancer research. He also pointed out the 
necessity of experience exchange and collaboration 
between different institutes worldwide.
The goal of the Workshop was to discuss current 
views and newly emerging conceptual frameworks 
concerning mechanisms of cancer development. 
Considering the fact that cancer is major healthcare 
problem today, the pursuit of deep understanding 
how cancer actually works will lead to new effective 
approaches to treatment of proliferative disorders. 
Accordingly, all lectures and reports, presented by par-
ticipants, included up-to-date issues and experimen-
tal data dealing with clinical and biological aspects 
of cancer research. The Workshop featured excellent 
lectures, delivered by invited speakers from Karolinska 
Institutet (Sweden) and speakers from IEPOR NASU, 
as well as informative reports on proceeding research.
The number of scientists, who took part in the event, 
reached more than hundred people this year. Apart 
of organizing institutes representatives of other institu-
tions also attended the Workshop. Among them there 
were Institute of Cell Therapy, City Clinical Oncological 
Center, National Cancer Institute of the Ministry of Pub-
lic Health of Ukraine, National University of Kyiv-Mohyla 
Academy, Center of Molecular and Cell Research, Taras 
Shevchenko National University of Kyiv, Educational and 
Scientific Center “Institute of Biology”, State Institution 
“Institute of Pharmaco logy and Toxicology, National 
Research Center for Radiation Medicine, Shupik Na-
tional Medical Academy of Post-Graduate Education, 
Reference-Centre for Molecular Diagnostic, Ovcha-
renko Institute of Biocolloidal Chemistry, Bogomolets 
National Medical University, Institute of Molecular Biol-
ogy and Genetics (Kyiv, Ukraine), Danylo Galytskyj Lviv 
National Medical University, Ivano-Frankivsk National 
Medical University, Rivne Region Oncology Hospital, 
Bila Tserkva National Agrarian University; Bila Tserkva 
Regional Oncology Center; Belarusian Research Сenter 
for Pediatric Oncology, Hematology and Immunology 
(Minsk, Belarus), Cancer Research Institute of SB of the 
RAMS (Tomsk, Russia), Institute of Chemical Biology 
and Fundamental Medicine of SB of the RAS (Novosi-
birsk, Russia).
The program of the Workshop spanned plenary lec-
tures and oral or poster reports. All talks evoked vivid 
interest among listeners and, thus, were thoroughly 
discussed. Some of these reports were included into 
current issue of Experimental Oncology journal for 
your appreciated consideration.
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PART I. LECTURES
TUMOR PROGRESSION — TIME FOR A NEW 
PARADIGM?
I. Ernberg, MD, PhD, Professor of Tumor Biology
Department of Microbiology, Tumor and Cell 
Biology, Karolinska Institutet, Stockholm SE-
17177, Sweden
Ingemar.Ernberg@ki.se
Around the millennium three decades of successful 
research into the biology of cancers were concluded 
in the most cited review on cancer ever “Hallmarks 
of Cancer” (Hanahan and Weinberg, Cell, 2000). 
It marked the end of the era when oncogenes and 
suppressor genes were discovered en masse, and 
when tumor progression at the level of cell and tissue 
pathology could be linked with molecular steps like that 
of the pioneering description by Bert Vogelstein of colon 
cancer progression (“The Vogelgram”). We then under-
stood that cancer was indeed a disease of cells and 
depended on mutations of some ten genes. Tumor pro-
gression, when tumors “go from bad to worse”, could 
be viewed as an evolutionary, Darwinistic process at the 
tumor cell population level, with sequences of mutation, 
improved cell survival, selection, another mutation etc. 
This seemed so transparent and logically sound that the 
scientific community at large believed it had understood 
the biology of cancer. Now we only needed to trace 
these mutated genes and eliminate their erroneous 
behaviour one way or another. It also gave a strong im-
petus to “personalized cancer medicine”, now we only 
needed the genome of individual tumors for designing 
the cure. One impressive major extrapolation was that 
all the 200 different forms of cancer develop through 
a similar mechanism. With this modern paradigm of can-
cer biology (or the Hanahan — Weinberg — Vogelstein/
HWV-paradigm) as a basis, ten years later it was clear 
that the success rate in exploiting its implications for 
cancer treatment was quite low.
During the same time the understanding of cell and 
tissue biology took quantum leaps in new directions, 
which clearly exposes the HWV-paradigm as totally 
insufficient and oversimplified, although not directly 
wrong. The conclusions are two: we do not really un-
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derstand cancer biology, and cancer is a very complex 
disease reflected by the enormous complexity of its 
“host” — the cell. Major findings have been: epigenetic 
deregulation is as important as mutations, cancer tis-
sues are highly heterogenous with cell hierarchies (in-
cluding stem-cell like cells) and a participating stroma, 
microRNAs represent a large new set of regulatory 
genes, low level chronic inflammation is a key compo-
nent in early carcinogenesis, there are not only some ten 
mutations in cancer cells but rather several thousands, 
and cancer cells usually switch metabolism from oxida-
tive glycolysis to fermentation (the Warburg effect).
How can we comprehend all these significant find-
ings in our understanding of cancer biology? Firstly 
we should be humble. Secondly we should explore new 
tools and technologies in interdisciplinary initiatives 
to adopt an approach that accommodates complex 
or complicated features of biological systems like can-
cer. This will be a long and uncertain way. Meanwhile 
it must be perfectly motivated to continue to develop 
treatments based on trial-and-error without sufficient 
information about the enemy.
EXPLOITING THE P53 PATHWAY TO ACHIEVE 
CURE IN CHRONIC MYELOGENOUS 
LEUKEMIA
S. Lain, PhD, Associated Professor
Department of Microbiology, Tumor and Cell 
Biology, Karolinska Institutet, Stockholm, Sweden
sonia.lain@ki.se
In 2008 we reported the discovery and antitumor 
activity of a small molecule named tenovin-6. In addition, 
we showed that this compound activates the tumour sup-
pressor p53 as well as inhibits the protein deacetylase 
activity of sirtuin SirT1. In 2012, a series of remarkable 
studies were published showing that tenovin-6 increases 
apoptosis in Chronic Myelogenous Leukemia (CML) stem 
cells and reduces their growth in vitro and in vivo in combi-
nation with imatinib. These exciting preclinical results have 
encouraged us to synthesize new tenovin-6 analogues 
and investigate their activity in cells and biochemical as-
says. Here I will present new findings obtained with our 
current collection of tenovin analogues and suggest which 
of these features may influence therapeutic activity. I will 
also discuss our progress in the identification and mecha-
nism of new compounds for testing in leukemia preclinical 
models and patient samples.
INDIVIDUALIZATION 
OF CANCER TREATMENT: SUCCESSES AND 
CHALLENGES
S. Souchelnytskyi, PhD, Associated Professor
Department of Oncology-Pathology, Karolinska 
Institutet, Stockholm, Sweden
serhiy.souchelnytskyi@ki.se
Biomedical research delivered a new look on the 
medicine. New developments of biochemistry, mo-
lecular biology, engineering, biomedical research 
deliver new insights in the cancer mechanisms, new 
treatment methods and new drugs.
Medicine success needs new techniques.
New techniques are coming from biochemistry, 
chemistry, physics, molecular and cell biology.
More than 100 anti-cancer drugs are used in the 
clinic today, and new drugs are under development 
for use tomorrow. The challenge is to match a patient 
with the right drugs. The clinicians face this challenge 
with practically every patient, because of the limita-
tions of diagnostics. Information obtained with current 
diagnostics is still far from predicting securely how 
the tumor and patient would respond to a treatment.
The recent developments of cancer research have 
opened for the qualitative improvement of diagnostics. 
We have developed Functional Molecular Diagnostics 
(FMDx) which is for the clinical use. FMDx tests re-
sponsiveness of individual patient’s tumors to different 
drugs by testing responsiveness of the living tumor 
samples in organ culture (Organ Culture FMDx), test-
ing targets and modulators of the drugs’ action (Func-
tional Biochemical Assays), and by unbiased testing 
of the tumor’s proteome profile (Proteomics FMDx).
FMDx is a set of assays performed on living and 
processed tumor cells following removal from patients 
upon surgery or biopsy. These assays measure in a real 
time how the patients’ tumor may respond to differ-
ent drugs before the patient is offered treatment, and 
whether the tumor is of an aggressive type. The suc-
cessfulness of FMDx is based on novel proprietary 
technologies.
FMDx assays are of 3 types — organ culture-based, 
functional biochemical assays and proteomics-based. 
The assays may be used all together or separately, 
depending on the clinical requirements. All 3 types 
of assays analyze a tumor with different methods, but 
for the common goal of finding the best treatment. 
This increases the confidence of the recommendations 
for treatment. FMDx has been used for diagnostics 
of cancer patients, and in my talk, Functional Molecular 
Diagnostics applications will be discussed.
HIGH-RISK HPV L1 CAPSID PROTEIN 
AS A MARKER OF CERVICAL 
INTRAEPITHELIAL NEOPLASIA IN HIGH-
RISK HPV-POSITIVE WOMEN WITH MINOR 
CYTOLOGICAL ABNORMALITIES
S. Andersson, MD, PhD, Professor
Department of Women’s and Children’s Health, 
Division of Obstetrics and Gynaecology, Karolinska 
Institutet, Karolinska University Hospital 171 76, 
Stockholm, Sweden
Sonia.Andersson@ki.se
Human papillomavirus (HPV) L1 capsid protein 
is only produced during a productive HPV infection 
at the end of the natural viral life cycle and is a major 
target of the immune response in women with HPV-
related squamous intraepithelial lesions.
We evaluated the usefulness of L1 detection by im-
munocytochemistry in high-risk (HR) HPV-positive 
women with minor cytological abnormalities detected 
at organised population-based cervical cancer 
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screening in Sweden, and assessed the relationship 
with histological diagnoses. Cytological slides were im-
munocytochemically stained using a HPV L1-specific 
monoclonal antibody for all known HPV types. HPV DNA 
analysis was performed by Linear Array. Out of 13 L1-
positive women infected with HPV16, only two (15.0%) 
progressed to cervical intraepithelial neoplasia grade 
2 or worse (CIN2+); compared to four L1-positive 
women infected with other HR-HPV types. Among 
L1-positive women with CIN2+, 35.7% harboured both 
HR and low-risk HPV types, 25.0% harboured HR-HPV 
types only, and 13.3% were infected with HPV16. Loss 
of L1 expression could be a prognostic marker for the 
development of preinvasive cervical lesions. We show 
that different HPV types may initiate a parallel onco-
genic process, but only loss of L1 expression predicts 
the development of CIN2+, suggesting that HPV typ-
ing in combination with L1 detection could be used 
for more focused investigations of women with minor 
cytological abnormalities.
CARCINOMA OF THE ENDOMETRIUM: 
PREDICTION MARKERS OF TUMOUR 
PROGRESSION, AGGRESSIVENESS AND 
POTENTIAL TARGETS FOR THERAPY 
IN A MITOCHONDRIAL PERSPECTIVE
M. Mintz, MD, PhD, Associated Professor
Department of Women’s and Children’s Health, 
Division of Obstetrics and Gynaecology, Karolinska 
Institutet, Karolinska University Hospital 171 76, 
Stockholm, Sweden
Miriam.Mintz@ki.se
Endometrial cancer (EC) is the most common 
gynaecological cancer in the Western world, and its 
incidence continues to increase. At present, molecular 
markers are not commonly used to detect EC, nor are 
there molecular markers that can distinguish between 
the more and less aggressive forms of EC. Treatment 
is currently based on histological results from a single 
pre-surgical endometrial biopsy, which is often quite 
different from the biopsy obtained during surgery. 
There is a clear need for early molecular markers 
that can be used to determine EC diagnosis, as well 
as tumour progression and aggressiveness, in order 
to improve the prognosis of EC and to reduce recur-
rence. Further investigation of tumour gene mutations 
is also needed to find new targeted treatments for EC.
We summarized the known molecular alterations 
that occur in EC, with a focus on mitochondrial al-
terations, and the potential to use these alterations 
to develop targeted treatments in the future. Studies 
concerning mitochondrial dysfunction in carcino-
genesis reported that the LRPPRC protein is highly 
expressed in early endometrial carcinogenesis, and 
may be considered an early marker of EC. Moreover, 
four proteins were reported to be molecular markers 
of aggressiveness in patients with EC: 1) the ratio 
of progesterone receptor (PR) A/PR B less than 1 was 
associated with a shorter disease-free period and 
shorter survival in patients with endometrioid EC; 2) 
glucose transporter proteins (GLUT 1 and GLUT 3) 
were correlated with increased malignancy, invasive-
ness and poor prognosis; and 3) the TKTL1 protein 
was overexpressed in low-grade EC.
Currently, there are no tumour markers that can 
resolve diagnostic problems in EC. The present review 
indicates that molecular markers and tumour char-
acteristics greatly vary. Consequently, a combination 
of molecular markers would be necessary to give 
information on early diagnosis, tumour progression 
and metastatic capability.
EBV-ENCODED EBNA-5 BINDS TO P18ARF 
AND PREVENTS P53-INDUCED GROWTH 
ARREST AND APOPTOSIS
E. Kashuba, PhD, Associated Professor
Institute of Experimental Pathology, Oncology and 
Radiobiology of National Academy of Sciences 
of Ukraine, Kyiv, Ukraine
MTC, Karolinska Institute, 171 77, Stockholm, 
Sweden
Elena.Kashuba@ki.se
The EBV transformed LCLs maintain wild type 
p53 during serial culturing. We addressed the question 
why the p53 downstream growth arrest and apoptotic 
pathways are non-functional in p53 expressing LCLs, 
unless activated by genotoxic agents, by examining 
p53 containing protein complexes in LCLs.
We have shown that trimolecular complexes were 
formed where MDM2 served as a bridge between 
EBNA-5 and p53. All three proteins colocalized in the 
nucleus of lymphoblastoid cells with a high p53 ex-
pression.
To explore the functional consequences of the 
MDM2–EBNA-5 binding, p53 polyubiquitination and 
degradation assays were performed in vitro. GST-
EBNA-5 inhibited MDM2-dependent polyubiquitina-
tion (but not monoubiquitination) of p53, similarly 
to GST-p14ARF. The p53 degradation on commer-
cially purified 26S proteasome subunits was inhibited 
by EBNA-5 as well.
These findings indicate that the high p53 levels 
in LCL are due to EBNA-5 dependent inhibition 
of p53 degradation. Chromatin immunoprecipitation 
showed that p53 could bind to the p21 promoter 
in mitogen stimulated but not the EBV activated 
B-cells. Taking together, these findings are con-
sistent with the interpretation that the trimolecular 
EBNA-5-MDM-2-p53 complex inhibits the binding 
of p53 to DNA.
We have cloned full length of human p14ARF pro-
tein (p18ARF) from the EST clone. We have shown 
by GST pull-down and transfections experiments that 
p18ARF binds to MDM2, MDMX, and EBNA-5. We have 
found that an enhanced expression of p18ARF in cells 
bearing wt p53 resulted in the cell death, similarly 
to mouse p19ARF. Simultaneous expression of p18ARF 
and EBNA-5 rescued these cells. Biological signifi-
cance of the binding between MDMX, p18ARF and 
EBNA-5 is currently under investigation.
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TRANSCRIPTIONAL NETWORK IN B CELLS: 
IRFS IN THE DEVELOPMENT OF B CELLS AND 
LYMPHOMAGENESIS
M. Yurchenko, L.M. Shlapatska, 
L.M. Kovalevska, S.P. Sidorenko
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology NAS of Ukraine, Kyiv, 
Ukraine
myurchenko@hotmail.com
The family of interferon regulatory factors (IRF) 
is comprised of 9 members: IRF1, IRF2, IRF3, 
IRF4/PIP/LSIRF/ICSAT/MUM1, IRF5, IRF6, IRF7, 
IRF8/ICSBP and IRF9/ISGF3γ. All members of this 
family of transcription factors contain the homo-
logical DNA-binding domain, which is responsible 
for interaction with DNA binding motifs ICS, ISRE, 
IRFE, EICE. IRF4 and IRF8 proteins share the most 
homology among other IRFs, and their expression 
is narrowed to the cells of immune system. For 
transcriptional regulation of target genes IRF4 and 
IRF8 form complexes with each other or with other 
transcription factors and adaptor proteins (Ets 
family — PU.1, SpiB, TEL; E47, NFAT, FOXP3, STAT 
proteins, MyD88, IBP, TRAF6). IRF1, IRF2, IRF4 and 
IRF8 play the central role in the regulation of im-
mune cells differentiation and maturation. IRF4 and 
IRF8 are key regulators of multiple steps of B cell 
differentiation, starting from stage of pre-B cells. 
IRFs 4 and 8 together with other transcription factors 
(BCL6, BLIMP1, XBP1, Pax5) control GC formation, 
CSR, memory versus plasma cell differentiation. 
IRF4 and IRF8 were shown to be deregulated in B cell 
malignancies. IRF8 was mainly shown to function 
as tumor suppressor protein, but IRF4 was found 
to be overexpressed in some tumors (multiple my-
eloma, Hodgkin’s lymphoma, some diffuse large 
B cell lymphoma cases, etc), and at the same time 
could have tumor suppressor functions in B-acute 
lymphoblastic leukemia.
Still there is not so much data on regulation 
of IRFs expression by different signals and signaling 
pathways in normal and malignant B cells. B cell re-
ceptor and CD40 are the most potent up-regulators 
of IRF4 expression. However, nothing is known about 
receptor-mediated downregulation of this transcrip-
tion factor. We have shown that CD150 receptor 
expression decreased the levels of IRF4 mRNA and 
protein in DT40 CD150+ transfectants — the stage 
of pre-B cells. Prolonged stimulation of activated 
human tonsillar B cells via CD150 resulted in up-
regulation of IRF4 mRNA. Signals via CD150 and 
BCR induced the upregulation of IRF4 mRNA ex-
pression by Burkitt’s lymphoma cells BJAB. Overall, 
CD150 and BCR had different impact on IRF4 ex-
pression by malignant and normal human B cells. 
The identification of surface receptors and signaling 
pathways involved in the regulation of IRFs expres-
sion could help to develop new strategies for tumor 
cells elimination.
IMMUNOGENIC CANCER CELL DEATH: HOW 
IT CAN BE EXPLOITED
L. Skivka
Taras Shevchenko Kyiv National University, Kyiv, 
Ukraine
realmed@i.com.ua
When considering normal, non-transformed 
cells, it is commonly assumed that the immunologi-
cal consequences of cell death follow a classical 
dichotomy of immunogenic necrosis versus non-
immunogenic (or even tolerogenic) apoptosis. 
However, recent studies have revealed that apop-
totic tumor cells induced by ionizing irradiation, 
anthracyclines and some other cytotoxic agents 
are able to induce a potent immune response 
in vivo. This led to the hypothesis that cell stress 
or death may result in the release of endogenous 
danger signals that act as adjuvants to stimulate 
an immune response. Some characteristics of the 
plasma membrane, acquired at preapoptotic stage, 
can cause immune effectors to recognize and at-
tack preapoptotic tumor cells. Depending on the 
signal-transduction pathway, tumor cells respond-
ing to chemotherapy or radiotherapy can express 
“danger” and “eat me” signals on the cell surface 
(such as NKG2D ligands, heat-shock proteins and 
calreticulin) or can secrete/release immunostimu-
latory factors (such as cytokines and high-mobility 
group box 1) to stimulate innate immune effectors. 
These endogenous danger signals (or alarmins) 
promote activation of innate immune cells and 
recruitment and activation of antigen-presenting 
cells engaged in host defense through pattern rec-
ognition receptors such as the TLRs, many of which 
have a key role in the detection of pathogens. 
In addition, these danger associated molecules 
act broadly with many other immunostimulatory 
molecules (endogenous and exogenous including 
pathogen associated molecular patterns or PAMP) 
to amplify their activity in a synergistic manner. 
In our investigations we used cytotoxic drug NSC-
631570 in combination with PAMP in the treatment 
of melanoma B16 bearing mice. Our results suggest 
that bacterial adjuvants synergized with chemo-
therapy to inhibit tumor growth and significantly 
augment immune responses. Current evidence 
suggests that once in the extracellular milieu, 
alarmins can bind to molecules such PAMP and, 
depending on its interactions with DNA, can form 
complexes of varying structure and with a vary-
ing the number of components. Here we analyse 
the current know ledge and our data to discuss 
the hypothesis that the formation of extracellular 
complexes is an important mechanism for gener-
ating pro-inflammatory signals during cell death 
and reverting some of the established immuno-
supressive barriers present within the tumor mi-
croenvironment, ideally recovering the role of the 
tumor as an effective immunogenic hub.
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HUMAN BETA-DEFENSINS IN REGULATION 
OF BIOLOGIC PATTERNS OF CANCER CELLS
O. Gerashchenko, E. Zhuravel, P. Pogrebnoy, 
M. Soldatkina
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology NAS of Ukraine, Kyiv, 
Ukraine
pogrebnoy@onconet.kiev.ua
Human beta-defensins (hBDs) belong to a family 
of small cationic peptide antibiotics produced by human 
epithelial cells and are characterized by wide spectrum 
of biologic activities. These molecules exert direct anti-
microbial action and immunomodulatory activity, and are 
shown to be involved in many human pathologies including 
cancer. Beta-defensins are involved also in wound heal-
ing processes and may affect proliferation of epithelial 
cells. To understand the mechanisms of biologic activities 
of beta-defensins, we have produced two recombinant 
defensins — hBD-2 and hBD-4 expressed in bacterial cells 
as GST-hBD-2 or -4 fusion proteins. Analysis of in vitro ac-
tivity of rec-hBD-2 toward different human cancer cell lines 
(A341, A549, 3 thyroid cancer cells, 2 melanoma cell lines) 
has demonstrated that this defensin is capable to affect 
cell proliferation and viability in a concentration-dependent 
manner and in nanomolar range may significantly sup-
press cell growth via cell cycle arrest in G1/S checkpoint, 
dephosphorylation of pRB and significant suppression 
of cyclin D1 expression. The action of hBD-2 is not cell 
type specific, at nanomolar concentrations hBD-2 signifi-
cantly suppresses colony forming activity of human cancer 
cells and their migration ability in scratch assay. In vitro 
hBD-2 may enter tumor cells, could be detected in cell 
cytoplasm and also in cell nuclei. Similarly, this defensin 
has been detected in cell nuclei in human lung tumor 
samples, moreover, in such cases hBD-2 expression levels 
positively correlated with human lung adenocarcinoma 
differentiation grade, and negatively correlated with PCNA 
expression. Hypothetically, concentration-dependent ef-
fects of hBD-2 could be explained by its capability to oligo-
merization. The study of recombinant hBD-4 (presented 
in details in current issue of Exp Oncol) has demonstrated 
a concentration-dependent bimodal effect of this defensin 
on biologic patterns of human cancer cells: in low nano-
molar concentrations rec-hBD-4 significantly stimulates 
cancer cell proliferation and viability, promotes cell cycle 
progression through G2/M checkpoint, greatly enhances 
co lony-forming activity and migration ability of the cells, 
but at higher concentrations the effects are of opposite 
character — significant suppression of cell proliferation 
and viability, cell cycle arrest in G1/S checkpoint, signifi-
cant inhibition of cell migration and colony forming activity. 
It’s of interest to analyze further with the use of in vitro 
system what mechanism is exploited by beta-defensins 
for cancer cell growth suppression — senescence, MET, 
other, whether it is reversible or irreversible, and to find ap-
plications of this know ledge in the field of clinical oncology.
PART II. ORAL AND POSTER PRESENTATIONS
NEW MECHANISMS OF CLINICAL 
EFFICACY OF LOW-DOSE METRONOMIC 
CHEMOTHERAPY TREATMENT OF PATIENTS 
WITH METASTATIC COLORECTAL CANCER
Yu.I. Kudryavets1, N.O. Bezdenezhnykh1, 
G.I. Maksim̓yak2, V.E. Zhylchuk2,3, 
I.M. Adamenko1, N.I. Semesiuk1, 
A.L. Vorontsova1, O.E. Sichkoriz3, V.F. Chekhun1
1R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology NAS of Ukraine, Kyiv, 
Ukraine
2Rivne Region Oncology Hospital, Rivne, Ukraine
3Danylo Halytsky Lviv National Medical 
University, Lviv, Ukraine
kudrayvets@mail.ru
Background and Aim: This work describes the 
experience of treatment of metastatic colorectal cancer 
(mCRC) patients with liver metastases (stages T1–4N0–
2M1) by low-dose chemotherapy (LDCT) in metronomic 
regimen including interferon-alpha (IFN), and dem-
onstrates growth behavior and immunophenotypical 
changes in CRC cells after influence of LDCT in vitro. 
Patients and Methods: Treatment of 254 patients was 
carried out using different schemes, which included 
cyclophosphamide, cisplatin (CP) and irinotecan (IT) 
with IFN, efficiency of therapy was monitored by clini-
cal methods and computer tomography. Cell culture 
and immunocytochemical methods were used for 
in vitro investigation. Statistical analysis using the 
Student’s t-test and Kaplan — Meier survival curves. 
Results: Metronomic mode of LDCT in patients with 
mCRC demonstrated high performance compared 
with conventional treatment using only high dose 
of IT. Among the most effective schemes metronomic 
mode of application of LDCP and IT combination was 
shown: duration of partial clinical effect was nearly 3 fold 
higher, duration of the stabilization process and the 
overall survival rate increased respectively by 81% and 
34.5% in comparison with a high dose IT therapy. Using 
of IFN in all the metronomic CT schemes significantly in-
creased their effectiveness. We have found new targets 
in the CRC cells for the effects of LDCT in vitro. Cells 
of human colorectal adenocarcinoma of COLO 205 line 
were cultivated in vitro with LD (10–20 times lower 
IC50) of IT, CP, IFN and their combination for 30 days. 
The ability of cells after prolonged exposure by LDCT 
to the agar colony formation decreased by 3–5 times, 
the maximal effect was observed with the combination 
of IT + CP + IFN (from 9.25% to 0,25%). A significant 
decrease of number of cells with mesenchymal and 
malignant stem cell characteristics was found: num-
ber of N-cadherin-, SLUG- and CD44-positive cells 
decreased more than 10 fold for various combina-
tions of drugs. Expression of ERCC1 marker in COLO 
205 cells completely disappeared in all combinations 
with IFN, but increased somewhat under the influence 
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of IT + CP. At the same time sensitivity of this cells 
to drugs in IC50 doses didn’t change. Conclusions: 
Low-dose metronomic chemotherapy of patients with 
mCRC is a new and perspective approach that provides 
suppression of the disease progression. LDCT drugs 
inhibit signs of epithelial-mesenchymal transition and 
malignant phenotype in CRC cells in vitro.
THE COMET ASSAY: APPLICATIONS 
TO STUDY CANCER RISK INFLUENCED 
BY EXTERNAL EXPOSURE
O. Bilyk, O. Brieieva, L. Buchynska
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine, Kyiv, 
Ukraine
lenabilyk@gmail.com
Introduction: The comet assay is a reliable method 
for measuring DNA damage and repair in human cells 
such as lymphocytes, epithelial cells, and tumor cells 
of different origin and has applications in genotoxicity 
studies, bio-monitoring and cancer research. The poten-
tial use of assay as a tool for estimation an individual can-
cer risk in patients with high predisposition to cancer and 
clinical management of cancer is widely discussed. Aim: 
To study DNA damage and repair capacity in epithelial 
cells and peripheral blood lymphocytes (PBL) after expo-
sure to genotoxic agents in healthy and cancer patients 
with family history of cancer. Methods: PBL from 45 en-
dometrial cancer (EC) patients were exposed to bleo-
mycin for 30 min. DNA repair capacity was assessed 
after 15 min incubation in RPMI 1640 without bleomycin. 
Primary and immortalized by HPV16 E6/E7 oncogenes 
of ovarian surface epithelial (OSE) cell cultures ob-
tained from 5 women at high risk (HR) of ovarian cancer 
were exposed to mitomycin C (MMC) at concentration 
50 nmol/L. PBL from 10 healthy volunteers and 5 primary 
OSE cell cultures from women without family history 
of cancer were evaluated for DNA damage as a control. 
DNA damage was assessed by comet assay as a mean 
% of DNA in the tail and the comet tail moment (TM). 
Results: The level of basal DNA damage in PBL of EC pa-
tients was significantly higher (TM 2.1±0.2) compared 
to healthy volunteers (TM 0.2±0.1). Among EC patients 
the sensitivity of PBL to genotoxic exposure to bleomy-
cin was higher in patients with family history of cancer 
(TM 104.9±1.2) then in patients with sporadic cancer 
(TM 97.3±0.6). It has been found that efficiency of DNA 
repair in PBL of EC patients depended on family history 
of cancer. After 15 min repair PBL restored the damaged 
DNA to the level of TM 55.0±2.4 in EC patients with family 
history of cancer and up to 22.7±1.1 in patients with spo-
radic EC. Basal damage of DNA was significantly higher 
for the primary HR OSE cells than in control OSE cells 
(TM 15.1±0.1 and 1.0±0.2, respectively). Cell incubation 
with MMC resulted in progressive increasing of the level 
of DNA damage of HR OSE cells (TM 25.3±0.2) whereas 
normal OSE cell line was resistant to genetoxic expo-
sure (TM 1.1±0.5). After immortalization of OSE cells 
by HPV E6/E7 oncogenes the intensity of DNA damage 
significantly increased independently of family history 
of cancer. HR OSE cells immortalized with HPV E6/E7 on-
cogenes demonstrated increased sensitivity to genotoxic 
exposure compared to normal immortalized OSE cells 
(TM 88.5±0.1 and 16.0±0.1, respectively). Conclusion: 
Enhanced DNA damage of PBL and OSE cells in healthy 
and cancer patients with family history of cancer under 
genotoxic and viral oncogenes exposure could expand 
our understanding of endometrial and ovarian cancer 
etiology and biology. Comet assay is a useful tool for 
assessment of individual sensitivity to genotoxic and viral 
exposure to evaluate the risk of malignancy in patients 
with predisposition to cancer.
ANTITUMOR EFFECT OF OXY CORRELATES 
WITH ITS ABILITY TO DECREASE THE LEVEL 
OF NITROSYL-HEM COMPLEXES IN LEWIS 
LUNG CARCINOMA CELLS
I. Boichuk, O. Melnikov, G. Solyanik
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine, Kyiv, 
Ukraine
boichuk_irina@mail.ru
Introduction: It is known that the tumor growth 
is accompanied by changes of redox carriers in the 
mitochondrial electron transport chain. These changes 
may result in decrease of energy metabolism. The 
functional state of the mitochondrial electron transport 
chain also defines the intensity of production and ac-
cumulation of the oxygen and nitrogen reactive spe-
cies (ROS and NOS), which affect different biological 
processes and can promote cell damage. It has already 
been observed that non-cytotoxic doses of oxyres-
veratrol (OXY) showed significant antineoplastic and 
anti-metastatic effects and prolonged the life of animals 
with tumors. Aim: To analyze the influence of OXY on the 
mitochondrial iron-sulfur centers and nitrosyl-hem 
complexes of tumor cells during Lewis lung carcinoma 
growth. Materials and Methods: EPR method was 
used to analyze the OXY influence on the content of the 
mitochondrial iron-sulfur centers (g=1.94) and nitrosyl-
hem complexes (g=2.007) in tumor tissues. The total 
dose of OXY was 0.2 mg/g of animal weight. The agent 
was administered per os from the 2nd day after cancer 
cell inoculation, 5 times/week, during 3 weeks. Tumor 
volume as well as characteristics of tumor mitochondrial 
electron transport chain was registered on the 10th, 14th, 
16th, 20th, 25th day of the tumor growth. Results: It was 
shown that OXY affected the formation of nitrosyl-hem 
complexes in mitochondrial electron transport chain. 
In OXY free mice the level of nitrosyl-iron complexes 
was significantly increased during tumor growth, while 
the level of iron-sulfuric centers was progressively 
decreased. Treatment of LLC-bearing mice with OXY 
resulted in a considerable LLC growth inhibition and 
caused the reduction of NO-hem complexes. Its level 
at the end of the treatment (20th, day of tumor growth) 
was by 64% (р < 0.05) lower than that of control mice. 
In 5 days after therapy completion the level of NO-
hem complexes in OXY treated mice was not changed 
compared to untreated animals. It was shown that OXY 
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didn’t influence the content of iron-sulfuric centers 
in LLC. Conclusions: LLC growth is accompanied 
by decrease of iron-sulfur centers’ content and increase 
of nitrosyl-hem complexes in mitochondria of cancer 
cells. Decrease of the level of nitrosyl-hem complexes 
in cancer cells under OXY treatment correlates with 
an ability of OXY to inhibit LLC growth.
COMBINED APPLICATION OF AUTOLOGOUS 
AND XENOGENEIC HEAT SHOCK PROTEINS 
IN VACCINOTHERAPY OF MALIGNANT 
TUMORS
I. Boliukh, G. Didenko, G. Potebnya
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine, Kyiv, 
Ukraine
tavrovska_1@mail.ru
Introduction: The use of immunotropic substanc-
es of natural and synthetic origin, including heat shock 
proteins (HSP) is one of the successful strategies 
to improve the efficiency of existing tumor vaccines. 
Aim: Combined application of heat shock proteins 
derived from the chicken xenogeneic embryonictissue 
and from autologous tumor cells for creating effective 
antitumor vaccines. Methods: Protein extracts from 
embryonic and tumor tissue were obtained by protein 
ammonium sulphate salting-out. Column chromatog-
raphy was used for HSP separations with molecular 
weight of 70 kDa. HSP were analyzed by western blot 
with anti-HSP-70 monoclonal antibody (Enzo, USA). 
Based on HSP fraction, a number of vaccines were 
constructed and their efficacy was analyzed in vivo 
in Balb/c and C57Bl/6 mice with transplantable Ehrlich 
carcinoma and Lewis lung carcinoma (3LL). All animals 
were divided on 6 groups consisting of 10 animals 
each. Antitumor effect of vaccines was evaluated 
by the dynamics of tumor growth, survival rate and an-
timetastatic effect. Results: Immunoblot test demo-
n strated antigenic homology of HSP-70 derived from 
embryonic chicken tissues and Ehrlich carcinoma. 
It was found that level of HSP-70 was 1.68 times higher 
in chicken embryonic tissues compared to Ehrlich 
carcinoma. Vaccines enriched with HSPS 70 were 
made from tumor samples and chicken embryonic 
tissues and their antitumor efficacy, manifested in in-
hibition of tumor growth (IG 24.35%) and the increase 
in life expectancy of experimental animals, has been 
shown. The purification of HSP-peptide complexes 
in tumor extracts and embryonic tissues was made 
and on their basis a number of vaccines has been de-
veloped, antitumor activity of which has been tested 
in the system in vivo on animals with transplantable 
3LL. The effective vaccines stimulated cytotoxic 
activity of lymphocytes and macrophages (straight 
by 25% and antibody-dependent by 27%), increased 
serum cytotoxic activity and decreased the content 
of circulating immune complexes. Anticancer activity 
of vaccines was mainly reflected in the inhibition of me-
tastasis. Conclusions: Combined use of xenogeneic 
and autologous HSP-peptide complexes for design 
of vaccines significantly increases their antitumor 
activity and immunomodulating effect compared with 
the vaccine prepared by the traditional technology.
MISMATCH REPAIR PROTEINS MSH2, 
MLH1 EXPRESSION AND DNA DAMAGE 
IN TUMOR CELLS OF ENDOMETRIAL 
CANCER PATIENTS WITH FAMILY HISTORY 
OF CANCER
O. Brieieva, N. Iurchenko, L. Buchynska
R.E. Kavetsky Institute of Experimental Pathology, 
Oncology and Radiobiology, NAS of Ukraine, Kyiv, 
Ukraine
olha.brie@gmail.com
Introduction: DNA repair deficiency may cause 
genetic instability that results in high sensitivity of cells 
to exogenous and endogenous DNA damaging agents. 
Mismatch repair has important role in the maintenance 
of genome integrity in tissues with high proliferative 
activity such as endometrium. Genetic and epigen-
etic defects of mismatch repair genes MSH2 and 
MLH1 induce accumulation of mutations leading 
to malignant transformation. Patients with family his-
tory of cancer may be characterized by inherited DNA 
repair deficiency therefore further studies are needed 
to assess DNA repair activity in these patients. Aim: 
To evaluate the level of DNA damage and mismatch 
repair activity in tumor cells of endometrial cancer pa-
tients considering family history of cancer. Methods: 
20 endometrial cancer (EC) patients with the mean 
age 57.2 years were included in the study. Assess-
ment of DNA damages in endometrial tumor cells was 
performed by DNA comet assay. The level of DNA dam-
age was quantified as the mean percentage of DNA 
in the tail and the comet tail moment (TM). Mismatch 
repair activity was assessed by immunohistochemistry 
using primary monoclonal antibodies MSH2 (clone 
25D12) and MLH1 (clone G168–15) (“Diagnostic Bio-
Systems”). The mean percantage of immunopositive 
cells was calculated (LI, %). Results: 30% of EC pa-
tients had family history of gastrointestinal tract and 
female reproductive system cancers. Assessment 
of DNA damage in endometrial tumor cells revealed 
that TM equaled to 32.2±1.2 and the % DNA in comet 
tail — 51.7± 1.3. It was found that level of DNA dam-
age in tumor cells of EC patients with family history 
of cancer was almost two times higher (TM 50.4±2.9; 
% DNA in comet tail 75.72±1.96) compared to sporadic 
EC (TM 27.3±1.2; % DNA in comet tail 45.2±1.5). 
Immunohistochemical study didn’t reveal significant 
difference of MSH2 expression in EC of patients with 
and without family history of cancer (LI 40.0±3.4% and 
40.5±7.7%, respectively). Expression of MLH1 was 
higher in sporadic EC (LI 45.8±2.3%) compared 
to EC of patients with family history of cancer 
(LI 37.8±4.9%). Conclusions: Endometrial cancer 
cells of patients with family history of cancer are char-
acterized by increased level of DNA damage that may 
be caused by low level of MLH1 protein expression 
indicating abnormalities of mismatch repair capacity.
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THE INFLUENCE OF THE PELVIC PLEXUS 
PRESERVATION UNDER RADICAL 
HYSTERECTOMY IN PATIENTS WITH 
INFILTRATIVE CERVICAL CANCER ON THE 
CONTRACTILE FUNCTION OF THE URINARY 
BLADDER
T. Dermenzhy, V. Svintsitsky, I. Schepotin, 
O. Iatsyna, O. Kabanov
National Cancer Institute, Kyiv, Ukraine
nacluf@mail.ru
Aim: To justify the need to preserve pelvic plexus un-
der radical hysterectomy (RH) in patients with infiltrative 
cervical carcinoma (CC). Patients and Methods: 30 pa-
tients with infiltrative CC (mean age 32.7±4.9 years) which 
underwent RH were enrolled into study: in 15 patients 
(group I) RH was performed with preservation of the pelvic 
plexus and in 15 patients (group II) RH was performed 
by standard method without preservation of the 
pelvic nerve plexus. The study protocol was approved 
by Ethical committee permission of National Cancer 
Institute (Kyiv, Ukraine). Cytomanometric assessment 
of urinary bladder’s contractile function after RH with 
preserving of the pelvic plexus in infiltrative CC patients 
was performed by using urodynamic stand URO-PRO 
according to the standard procedure. Results: Accord-
ing to cytomanometric data contractile function of urinary 
bladder was fully restored in 2–3 days after RH in 80% 
of group I patients and only in 20% of group II patients. 
In patients of group II the function of the lower urinary 
tract restored within 7 days after RH, in 20% of these 
patients persistent paresis of the urinary bladder detrusor 
was observed, which partially restored from 7 to 21 days. 
It indicates strong neurological disorders of contractile 
function of urinary bladder under surgical trauma of pel-
vic plexus during standard RH. Conclusion: Recovery 
of the contractile function of urinary bladder in 24 hours 
after RH justifies necessity of the pelvic plexus preserva-
tion during RH in patients with infiltrative CC.
ALTERATIONS IN FUNCTIONAL PROPERTIES 
OF BONE MARROW STEM CELLS 
IN CHRONIC MYELOID LEUKEMIA PATIENTS 
WITH DIFFERENT RESPONSE TO TYROSINE 
KINASE INHIBITORS TREATMENT
M. Diachenko1, N. Bilko1, I. Dyagil2
1National University of Kyiv-Mohyla Academy, 
Center of Molecular and Cell Research, Kyiv, 
Ukraine
2National Research Center for Radiation Medicine 
NAMS of Ukraine, Kyiv, Ukraine
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Introduction: It has been revealed the relative qui-
escence and resultant therapeutic resistance of primitive 
chronic myeloid leukemia (CML) progenitor cells providing 
a basis for identifying the hematopoietic developmental 
stage of chronic phase initiating events, such as altered 
stem cell differentiation and survival. This survival advan-
tage is largely mediated by leukemic stem cells (LSCs) 
microenvironment. Aim: The aim of this study was to de-
termine the functional characteristics of hemopoietic and 
mesenchymal stem cells from CML patients with different 
response to the tyrosine kinase inhibitor (TKi) Imatinib (No-
vartis). Patients and Methods: All 32 patients who were 
treated with TKi between 0 and 41 month have undergone 
cytogenetic analysis for the Philadelphia chromosome 
as well as in vitro assays: CFU-A in the semisolid agar 
and suspension cultures. According to the TKi therapy 
response patients were divided into groups: with optimal 
response (no Ph+ cells), suboptimal response (Ph+ > 
0%) and the group of patients who received hydroxyurea 
before TKi treatment. Results: The functional activity 
of bone marrow progenitor cells of patients with an opti-
mal response to therapy was significantly lower (p <0.05) 
compared to patients with resistance to the therapy (the 
average CFU-GM numbers 29.3 and 79.3, respectively). 
Leukemic progenitor cells from CML patients were able 
to survive in stroma-free suspension culture without 
any additional growth factors supplementation during 
21 day (median survival of 10 days). Such autonomous 
growth, not typical for normal cells, could be explained 
by autocrine mechanisms in primitive leukemia cells. 
Mesenchymal stem cells (MSCs) from CML patients 
with suboptimal response to TKi therapy showed 6 fold 
increases in proliferation rate compared to MSCs from 
bone marrow of patients with optimal response, sug-
gesting that stem cell microenvironment is also involved 
in transformation process. Conclusions: Our data indi-
cate the presence of individual response to the TKi therapy 
in CML’s patients that is probably associated with specific 
changes in the population of stem and progenitor cells due 
to alterations of their functional activity. Further researches 
of leukemic stem cells and their niche would allow better 
understanding of mechanisms of drug resistance and 
disease progression.
THE FREQUENCY OF HORMONE-RELATED 
TUMORS IN BREAST CANCER PATIENTS 
AFTER SURGICAL TREATMENT
I.B. Djakiv, A.E. Kryzhanivska
Ivano-Frankivsk National Medical University, 
Ivano-Frankivsk, Ukraine
irynadjakiv@ukr.net
Introduction: The frequency of hormone-related tu-
mors is about 20%, among which 10.8% belong to breast 
cancer (BC). Women with BC have increased risk of de-
veloping a new primary cancer in the opposite breast and 
second tumors of different localization that can be linked 
to genetics and hormonal risk factors. However, there 
is no data about the frequency, character and preventive 
measures of origin of the second hormone-related tumors 
in BC patients. Aim: To study the frequency of malignant 
tumors in women who were treated for BC. Methods: 
We have analyzed clinical data of 51 BC patients with stage 
I–IV. The patients’ age varied from 26 to 76 years (the mean 
age 54.3). Immunohistochemical staining of BC samples 
was performed using the primary monoclonal antibo dies 
against progesterone (PR) (clon 1A6, “Dako”, Denmark), 
estrogene (ER) (clon 1D5, “Dako”, Denmark) receptors 
and HER2/neu (cerv2 oncoprotein, “Dako”, Denmark). 
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28 (54.9%) BC patients received neoadjuvant treatment 
and all patients received complex treatment including 
surgery. The study was approved by the local Institutional 
Ethic Committee. Results: BC of stage I was diagnosed 
in 8 (15.7%), stage II — 33 (64.8%), stage III/IV — 
10 (18.6%) patients. In BC patients second oncological 
pathology has been developed: in 19 (37.3%) patients — 
endometrial cancer, in 10 (19.6%) patients — ovarian can-
cer, in 7 (13.7%) — cervical cancer, in 2 (3.9%) — cancer 
of vulva, in 9 (17.6%) — colorectal cancer, in 1 (1.9%) — 
stomach cancer, in 1 (1.9%) — thyroid gland cancer and 
in 1 (1.9%) — kidney cancer. Family history of cancer 
with prevalence of BC was observed in 32 (62.7%) 
patients. Immunohistochemical phenotype ER+HER2/
neu+ was detected in 45 (88.2%), PR+ER+HER2/neu++ — 
in 10 (19.6%) and PR+ ER+ HER2/neu+++ — in 3 (5.9%) 
BC samples. Conclusions: Oncogynaecological tumors 
occupy the first place (74.5%) among hormone-related 
tumors in BC patients. The further study of risk factors for 
developing second malignant tumors in BC patients after 
treatment is needed.
EVALUATION OF INTRAPERITONEAL 
HYPERTHERMIC CHEMOPERFUSION 
EFFICIENCY FOR CHEMORESISTANT 
OVARIAN CANCER
U. Dutchak, M. Fetsych
Danylo Galytskyj Lviv National Medical 
University, Lviv, Ukraine
Uliasia3@rambler.ru
Introduction: Intraoperative hyperthermic intra-
peritoneal chemoperfusion (HIPEC) is a new method 
of combined treatment of chemoresistant ovarian 
cancer (OC) with peritoneal carcinomatosis, which ef-
ficiency was not fully determined. Aim: To improve the 
efficiency of treatment of patients with chemoresistant 
recurrent ovarian cancer after cytoreductive operation 
with HIPEC. Patients and Methods: We conducted 
a full clinical examination and treatment of 181 patients 
with recurrent OC, including 72 patients with chemore-
sistant recurrent OC. Depending on the treatment of OC, 
patients were divided into three groups. The first group — 
72 patients who received systemic chemotherapy: 1A 
group — 17 patients with chemoresistant recurrent OC, 
1B group — 55 patients with chemosensitive recurrent 
OC. The second group — 61 patients who underwent 
cytoreductive operation and systemic chemotherapy: 2A 
group — 29 patients with chemoresistant recurrent OC, 
2B group — 32 patients with chemosensitive recurrent 
OC. The third group — 48 patients who underwent cyto-
reductive operation, HIPEC and systemic chemotherapy: 
3A group — 26 patients with chemoresistant recurrent 
OC, 3B group — 22 patients with chemosensitive recur-
rent OC. Results: Median of survival for patients, who 
received combined treatment including cytoreductive 
operation and HIPEC with systemic chemotherapy, 
was 27 months and median of survival for patients with 
chemoresistant recurrent OC, who received treatment 
including cytoreductive operation with systemic chemo-
therapy without HIPEC, was 18 months, median of sur-
vival for patients, who received treatment with systemic 
chemotherapy, was 10 months. Procedure of HIPEC 
didn’t increase the frequency of surgical complications 
and postoperative lethality in OC patients. Surgical com-
plications after cytoreductive operation and HIPEC was 
observed in 10 (21%) patients, after cytoreductive opera-
tion without HIPEC — in 14 (22.9%) patients. Postopera-
tive lethality after the procedure of HIPEC was observed 
in 2 (4.2%) patients, and in 3 (4.9%) patients after the 
procedure of HIPEC. Conclusions: Application of HIPEC 
in combined treatment of patients with chemoresistant 
recurrent OC evidently increases survival of patients.
PROGNOSTIC VALUE OF SCCA TUMOR 
MARKER IN PATIENTS WITH CERVICAL 
CANCER
L. Vorobijva, I. Goncharuk, S. Nespryadko
National Cancer Institute, Kyiv, Ukraine
goncharuk_irina@i.ua
Squamous cell carcinoma antigen (SCCA) level 
in blood serum is proven to be valuable for diagnosis 
and monitoring of patients with cervical carcinoma. 
Since cervical carcinoma as a rule originates from 
squamous epithelium, SCCA estimation in blood se-
rum is significant for the study of the disease develop-
ment. The aim of the study was to monitor SCCA level 
in patients with cervical carcinoma with primary and 
metastatic disease for determination of recurrence 
probability value. Patients and Methods: Changes 
in SCCA level in blood serum and clinical data were 
analyzed in 224 patients with cervical carcinoma 
of I-IV stage. Primary cancer was diagnosed in 171 pa-
tients; recurrence was confirmed in 53 patients. SCCA 
concentration in blood serum was determined 
by chemiluminescent immunoassay at micro particles 
(HIAM). Statistical analysis was performed with the 
use of Statistica 6.0 software. The study protocol was 
approved by Ethical Committee permission of Na-
tional Cancer Institute (Kyiv, Ukraine). Results: It was 
shown that SCCA values different reliably in groups 
of patients with different development of the disease 
(p<0.05). SCCA level in patients with Ca in situ and 
IA stage was equal to 0.6 ± 0.1 and 0.9 ± 0.1 ng/mL, 
respectively. At the higher stage of the disease, the 
higher SCCA level in blood serum was detected (l 5.9 ± 
1.4 ng/mL in IIIB stage). It was confirmed that SCCA 
level in patients with primary cervical cancer with 
metastases in regional lymph nodes was higher com-
pared to SCCA level in patients without metastases 
(5.6 ±1.4 ng/mL vs 2.3 ± 0.1 ng/mL, p < 0.05). SCCA 
level in blood serum increased up to 86.4% of patients 
with the recurrence and equaled 19.4 ± 3.7 ng/mL 
(from 0.5 to 70.0 ng/mL). SCCA value in blood serum 
increased up to 60.4% of patients with cervical carci-
noma of IB-III stage. Test-sensitivity increased from 
7.8% (I stage) to 77.8% (III stage). Conclusion: SCCA 
level in blood serum can be considered as a sensitive 
method in prognostic study and determination of dis-
ease stage in patients with cervical carcinoma.
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OVARIAN TISSUE CRYOCONSERVATION 
IN PATIENTS WITH GYNECOLOGICAL 
CANCER
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Introduction: During recent years the increase 
in incidence rate of gynecological malignancies in re-
productive age patients, who had no time to implement 
reproductive function, has been registered. In majority 
of cases special treatment results in partial or full depri-
vation of fertility as a result of the high ovarian sensitivity 
to chemotherapy and radiation therapy. Cryopreservation 
and autotransplantation of ovarian tissue appear to be-
come the method of fertility preservation. Aim: To evalu-
ate the ovarian reserve and develop policy of treatment 
in patients with gynecological malignancies with the 
purpose of cryoconservation of ovarian tissue for further 
realization of reproductive function. Methods: 10 pa-
tients of reproductive age (< 35 years) have been treated 
in National Cancer Institute from 2010 to 2012 year with 
diagnosis IB–IIB stage cervical cancer. Panhysterectomy 
type 3 has been executed in 9 patients, radical abdominal 
trachelectomy — in 1 patient. Ovarian tissue obtained after 
laparotomy was placed in aseptic terms in container with 
special medium with temperature +20–25 °C and after that 
it was transported to Institute of Cell Therapy for following 
investigation, cryopreservation and storage. Currently all 
the patients are placed under dynamic surveillance. There 
is no evidence of the disease. The study protocol was ap-
proved by the Ethical Committee permission of national 
Cancer institute (Kyiv, Ukraine). Results: As a result, cryo-
conservation of ovarian tissue can be fulfilled with the aim 
to realize the delayed reproductive function. Conclusions: 
This method does not require the delay of the treatment, 
ovarian stimulation and can be accepted for the patients 
with gynecological malignancies.
MODERN CHEMOIMMUNOTHERAPY 
APPROACH BASED ON DENDRITIC CELLS 
AND LOW-DOSE CISPLATIN IN EXPERIMENT
A. Gorbach, N. Khranovska, O. Skachkova, 
R. Sydor, N. Svergun
National Cancer Institute, Kyiv, Ukraine
horbach.alex@gmail.com
Introduction: Nowadays, combined therapy 
based on dendritic cells (DC) and low-dose chemo-
therapy is intensively investigated worldwide. There are 
no commonly accepted regimens of combined therapy 
and development of efficient chemoimmunotherapy 
schemes remains an actual problem. Aim: To develop 
scheme of combined chemoimmunotherapy based 
on DC and low-dose cisplatin. Materials and Methods: 
120 CBA mice have been involved in the experiment. 
Sarcoma-37 was injected intramuscularly at lethal dose 
(2x106 cells per animal). Cisplatin was injected intra-
peritoneally 5 times in metronomic regimen according 
to the two schemes: 0.2 or 2 mg/kg on the 7th day after 
tumor transplantation with interval of 1 day and 3 days, 
respectively. DC vaccines were administered intrave-
nously 3 times on the 4 day after the chemotherapy. 
All experiments were approved by Ethical Committee 
permission of National Cancer Institute (Kyiv, Ukraine). 
Results: We have found that both chemoimmunotherapy 
schemes had significant antitumor and immunomodula-
tion effect. The most pronounced effect was observed 
with DC-vaccine and cisplatin at concentration of 2 mg/
kg in combination. Combination of DC vaccine and low-
dose cisplatin had a synergistic effect on the reduction 
of primary tumor. Significantly decrease of primary tumor 
volume in animals was received in combined therapy 
compared to the control (p = 0.001) and DC-vaccine 
(p = 0.007) groups have been found. We showed that 
administration of combined therapy improves survival 
by 20% in comparison with the control group. A signifi-
cant increase of cytotoxic activity of splenocytes in re-
sponse to allogeneic stimulation to 42.33 ± 4.8% in the 
combined therapy group compared to 29.67 ± 4.1% 
in the control group had been observed, p < 0.05. We also 
found that phagocytic activity of splenocytes in this group 
increased up to 52.33 ± 4.67% compared to 37 ± 5.29% 
in the control group, p < 0.05. The coefficient of reactive 
oxygen species induction was statistically significant 
and increased to 1.61 ± 0.23 in comparison with 1.05 ± 
0.13 in the control group. Conclusions: Low-dose che-
motherapeutics enhance the antitumor effect of DC-
based immunotherapy. These investigations form the 
basis to a new multimodality treatment of cancer patients.
THE ROLE OF CD150 SURFACE RECEPTOR 
IN REGULATION OF TOPOLOGY 
AND EXPRESSION OF P50 AND 
P65 NF-KB IN NORMAL B CELLS
I.M. Gordiienko, L.M. Kovalevska, 
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Introduction: CD150 receptor is widely expressed 
in hematopoietic cell lineage and is involved in lym-
phocyte activation, differentiation and apoptosis via 
regulation of signal transduction pathways. Moreover, 
CD150 is expressed on malignant cells at Hodg-
kin’s lymphoma and diffuse large B cell lymphoma that 
are characterized by enhanced level of NF-kB activa-
tion. CD150-mediated signal transduction pathways are 
not fully understood. Particularly, it is not clear whether 
CD150 is involved in regulation of NF-kB transcription 
factors that play a key role in immune system. Aim of our 
study was to find the potential role of CD150 in regula-
tion of NF-kB transcription factors function in normal 
human B-cells. Methods: Dense human tonsillar B cells 
were obtained in Percoll gradient, were stimulated via 
CD150 cell surface receptor, followed by immunofluo-
rescence staining with 3D deconvolution and Western 
blot analysis. Results: In dense B cells that comprise 
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IgD+ naive cells p65 was predominantly localized in cy-
toplasm and p50 — in the nucleus, while several p65/
p50 heterodimers were observed in nucleus, but not 
in cytoplasm. After 90 min of CD150 ligation p50 was 
also detected in cytoplasm. Stimulation of dense B cells 
via CD150 for 16 h resulted in complete translocation 
of p50 and p65 from nucleus to the cytoplasm. Further 
cell stimulation via CD150 up to 24 h resulted in return-
ing only p50 back to the nucleus, although, a high level 
of p50 was still observed in cytoplasm where it was co-
localized with p65. Western blot analysis has shown that 
after 24 hours of CD150 crosslinking on dense B cells, the 
expression level of p50 did not change, however, p65 lev-
el was slightly enhanced. The expression level of IkBα 
was significantly increased after 24 hour of CD150 liga-
tion that points on the role of IkBα in p65 and p50 subunits 
re-exportation from the nucleus and sequestering in the 
cytoplasm. Conclusions: CD150 is involved in regulation 
of gene expression in B cells via intracellular relocalization 
of both p50 and p65 and minor upregulation of p65 ex-
pression level. Thus CD150 may also contribute to the 
regulation of NF-kB1 activation in CD150 expressing 
malignant B lymphocytes.
MOLECULAR-GENETIC MARKERS FOR 
DIAGNOSIS AND PROGNOSIS IN PEDIATRIC 
SOLID MALIGNANCIES
N.M. Khranovska, N.V. Ionkina, N.M. Svergun, 
M.V. Inomistova, G.I. Klymnyuk
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Introduction: Molecular-genetic markers are very 
important tools for diagnosis and prognosis of solid 
tumors in children. Aim: To study chromosomal trans-
locations in patients with pediatric solid malignancies. 
Patients and Methods: Study has been performed 
on 279 tumor specimens, which were collected 
at diagnosis, and 90 specimens of bone marrow (BM) 
puncture biopsy from 200 patients with neuroblas-
toma (NB), 21 — Ewing sarcoma family tumors (ESFT), 
29 — alveolar rhabdomyosarcoma (ARMS), 29 — em-
bryonal RMS (ERMS). The study protocol was approved 
by Ethical Committee permission of National Cancer 
Institute (Kyiv, Ukraine). Chromosomal translocations 
were detected by fluorescence in situ hybridization 
(FISH) or real-time PCR on fresh or paraffin-embedded 
tissue samples. Results: Chromosomal translocation 
t(2;13)(q35;q14) exhibiting chimeric PAX3-FKHR and 
PAX7-FKHR gene products are the hallmarks of the 
ARMS. PAX-FKHR fusions were detected in 58 RMS 
samples: 10 (17,3%) had PAX3-FKHR and had 24 (41,4%) 
PAX7-FKHR fusions, 24 (41,3%) cases were fusion-
negative. PAX3-FKHR or PAX7-FKHR fusions were found 
in all ARMS. PA3/7-FKHR was detected in 5 of 29 patients 
with eRMS; it indicates the type of mixed type RMS 
and requires a change of tactics on the protocol for 
the treatment of ARMS. In addition, PAX3-FKHR fusion 
products were detected in biopsy tissue and BM from 
3 patients. ESFT is associated with chromosomal 
translocation t(11;22)(q24;q12). Out of the 21 samples 
with translocations detected, 16 (76.3%) had EWS-
FLI1 type 1, 1 (4.7%) had EWS-FLI1 type 2, 2 (9.5%) had 
EWS-ERG, 2 (9.5%) had EWS-ETV4 translocation. Fusion 
transcript EWS-FLI1 type 1 was found in BM of 6 patients. 
The most significant abnormality in NB is amplification 
of proto-oncogene MYC; its locus lies on the short arm 
of chromosome 1. In 44 (22%) cases of primary NBs 
amplification of MYCN gene is present. MYCN gene 
is a factor of unfavourable prognosis and influences the 
choice of treatment schedules. One sample with MYCN 
amp pos and 1p36 del pos, and 3 samples in MYCN amp 
neg and 1p36 del pos were detected. Loss of hetero-
zygosity (LOH) at 1p36 was independently associated 
with a worse outcome in NB patients. NB expresses 
the tyrosine hydroxylase (TH) mRNA, the first enzyme 
in the catecholamine pathway. TH expression was found 
in BM of 74 (37%) patients with NB. Molecular-genetic 
testing is more accurate than standard morphological 
methods; it enables detection of the presence of tumor 
cells in BM at diagnosis and during treatment, allows 
optimization of the treatment strategy. Conclusion: 
Molecular-genetic analysis helps to identify specific 
genes in children with solid malignancies in order 
to specify the diagnosis, prognosis; it also influences the 
selection of at-risk patients and treatment monitoring.
NUCLEIC ACID MARKERS IN BLOOD PLASMA 
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A.G. Kondratov1, K.A. Nekrasov1, L.V. Lototska1, 
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Introduction: Colorectal cancer (CRC) is the third 
commonly diagnosed cancer that causes 400 000 deaths 
worldwide. The most sensitive modern diagnostic tool 
of CRC is colonoscopy, which is a painful procedure 
and can not be recommended for patients with altered 
topography of colon. Aim: Development of less invasive 
tools for CRC screening based on detection of nucleic 
acids in blood plasma. Methods: Concentration of cell-
free circulating DNA in blood plasma was analyzed 
by qPCR. Methylation status of LRRC3B, APC, FHIT 
and HIC1 genes in cell-free circulating DNA of samples 
was determined by using methyl-specific PCR (MSP) 
with subsequent melting curve analysis. Results: It was 
shown that mean-value of cell-free blood plasma DNA 
is statistically higher in CRC patients than in healthy do-
nors (p < 0.01). Thus the mean-value of concentration 
of cell-free circulating DNA in blood plasma of CRC pa-
tients was 17.57 ± 3.43 ng/mL and 7.07 ± 0.84 ng/mL — 
in healthy donors. We have revealed hypermethylation 
of APC, FHIT and LRRC3B genes in 45% (10/22), 73% 
(16/22) and 68% (15/22) of tumor samples, respectively. 
Altogether hypermethylation of at least one of the se-
lected genes was detected in 95% (21/22) of samples. 
Using MSP with subsequent melting curve analysis 
we have detected methylated fragments of APC, FHIT 
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and LRRC3B genes in blood plasma of 29% (6/21), 19% 
(4/21) and 14% (3/21) of CRC patients, respectively. 
We have identified hypermethylation at least in one of the 
selected genes in 48% (10/21) of blood plasma samples 
of CRC patients. Additionally we have registered high 
frequency of HIC1 hypermethylation in blood plasma 
of CRC patients (8/10). We have suggested that two 
stage verification might be applied for CRC screening, 
which includes measurement of cell-free circulating DNA 
concentration with following detection of methylated 
fragments of APC, FHIT and LRRC3B genes in blood 
plasma of CRC patients. Overlapping of the above 
mentioned approaches allowed to increase sensitivity 
of studied panel up to 71% (15/21) in CRC detection. 
Conclusion: We have deve loped approach for screen-
ing of CRC which is based on determination of cell-free 
DNA and methylated fragment of well-known tumor 
related genes APC, FHIT, LRRC3B in blood plasma. The 
sensitivity of CRC detection might be increased by using 
of additional perspective genes like HIC1.
COMPLEX INFORMATION SYSTEM WITH 
WEB-INTERFACE CONCERNING BREAST 
CANCER
T.V. Pyatchanina, A.O. Koval, O.S. Dvorshchenko, 
M.B. Narolsky
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Introduction: Breast cancer (BC) is the most 
frequent cancer among women with an estimated 
17232 new cancer cases diagnosed in 2010 in Ukraine 
(19.9% of all cancers among women). As a result 
BC ranks as the first cause of death from cancer among 
women. BC is an actual social economical problem 
in Ukraine due to high rates of mortality and disability 
of women of active working age and requires significant 
funding. Economic situation in Ukraine gives priority 
to the prevention of BC, its most important component — 
increasing awareness of the public. Today a significant 
amount of information about BC has been accumu-
lated and solution of the problem can be accomplished 
through the use of up-to-date tools of information, such 
as electronic information technologies that offer quick 
access to large amounts of information. The primary 
tool of obtaining this information is a global Internet net-
work, but a significant amount of different information 
makes the problem of choosing the right materials more 
complicated. So there is a need for systematization and 
generalization of data to create a complex information 
system concerning BC. Aim: To develop the Ukrainian 
language information system about prevention, diag-
nosis and treatment of BC aimed on informing and self-
education of Ukrainian population as well as specialists 
in the medical field. Results: Technical specification for 
creation of a web-portal (conceptual, logical and physi-
cal design), software development, portal and template 
design, is developed. The site is filled up with thematic 
material content according to the designed structure. 
Created web-resource contains information concern-
ing BC, which uses brunched structure of the site and 
satisfies the information needs of the target audience — 
specialists in the field of medicine and ordinary citizens. 
Section of the site target audience, which defines the 
general population of Ukraine, is devoted to various 
aspects of BC in women such as questions disclosing 
BC risk factors, symptoms and diagnosis, primary pre-
vention, clinical classification of tumors and treatment. 
Module that contains data appointed to provide informa-
tion to medical specialists reflects the modern aspects 
of the pathogenesis of hormonal and molecular-genetic 
features of BC as a result of new post-genomic research. 
Conclusion: Complex Ukrainian language information 
system concerning nature, early symptoms, preven-
tion, diagnosis and treatment of BC as well as providing 
medical specialists with the latest structured scientific 
data about molecular biology of BC, has been created.
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CANCER STAGE IIB
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Introduction: One of the important tasks of mod-
ern oncogynecology is the estimation of biological 
characteristics of tumors. Among the biological mark-
ers studied in relation to cervical cancer, cyclooxygen-
ase-2 (COX-2) and vascular endothelium growth factor 
(VEGF) play an important role in the processes of the 
tumor invasion and neoanginogenesis. Aim: To deter-
mine the COX-2 and VEGF expression in tumors and 
their connection with clinico-morphological indicators 
of the efficiency of treatment in patients with cervical 
cancer. Patients and Methods: Operation materi-
als of 48 patients with cervical cancer stage IIB after 
chemotherapy was used. The immunohistochemical 
analysis of COX-2 and VEGF expression was per-
formed using primary monoclonal antibodies (MCAB) 
of the “Diagnostic BioSystems” company, USA (clone 
4H12) and “DakoCytomation”, Denmark (clone VG1) 
on the paraffin sections of the tumors. Results: A posi-
tive immunohistochemical reaction of specific MCAB 
to COX-2 was determined in 44 (92%) tumors, and 
to VEGF — in 42 (88%). It was shown that tumors with 
partial regression (PR), stabilization of the tumor pro-
cess degree II of pathomorphosis after the treatment 
and the disease recurrence are characterized by high 
levels of the COX-2 and VEGF expression. Tumors 
with PR and with degree III of pathomorphosis after 
the treatment and disease recurrence are character-
ized by high levels of the COX-2 and VEGF expression 
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but of low intensity. In patients with complete tumor 
regression after the treatment and without cervical 
cancer recurrence for more than 5 years no COX 
-2 and VEGF expressions were found. Conclusion: 
The results indicate that determining of the COX-2 and 
VEGF expression in tumor cells after treatment of pa-
tients could be considered as additional indexes for 
estimation of treatment efficiency and the prognosis 
of the cervical cancer course.
A COMPARISON OF MULTIPLEX SHORT 
TANDEM REPEAT PCR AND REAL-TIME PCR 
INSERTION/DELETION POLYMORPHISMS 
METHODS FOR QUANTIFICATION 
OF CHIMERISM AFTER HEMATOPOIETIC 
STEM CELL TRANSPLANTATION
V. Lavrinenko, T. Savitskaya, Y. Mareika
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Introduction: Quantitative monitoring of chime-
rism after allogeneic hematopoietic stem cell trans-
plantation (HSCT) by molecular methods has be-
come an indispensable diagnostic tool in detection 
of engraftment/graft failure, predicting rejection and 
disease relapse. Despite the great utility of chimerism 
analysis there is no unique standard method for its 
quantification. Aim: The objective of the present inves-
tigation was to compare the sensitivity (detection limit) 
and the quantification accuracy of two perspective 
methods: multiplex short tandem repeat polymerase 
chain reaction (STR-PCR) and real-time PCR insertion/
deletion polymorphisms (InDel-PCR) for the quanti-
fication of chimerism after stem cell transplantation. 
Methods: We performed a perspective study analyz-
ing the chimerism status in 46 patients by STR-PCR 
using AmpFlSTR SGM Plus PCR Amplification Kit (ABI, 
UK) with capillary electrophoresis and by InDel-PCR 
with primers and probes to 20 allele-specific markers 
and reference gene albumin. Results: Recipient-
donor discrimination was possible with STR-PCR 
in all patient-donor pairs (100%), whereas informative 
alleles for recipient were found in 94% pairs with InDel-
PCR. The sensitivity (detection limit) of STR-PCR was 
1–5% donor DNA with variation among STR markers. 
The sensitivity of InDel-PCR was more than 0.01% 
donor cells. The accuracy of quantification was higher 
for InDel-PCR than for InDel-PCR, when level of donor 
chimerism was <5% or >95% as it had higher sensi-
tivity. The accuracy of quantification was higher for 
STR-PCR than for InDel-PCR, when level of chimerism 
was >10%, because there was 0.5 threshold cycle er-
ror for InDel-PCR and this corresponded to a variation 
in DNA of 50%. The results obtained by two methods 
showed a good agreement and correlated well (r=0.98; 
p<0.0001). Conclusions: These methods can be suc-
cessfully used to determine chimerism after allogeneic 
HSCT. Considering the higher sensitivity and quanti-
fication accuracy of InDel-PCR it should be chosen 
if donor chimerism level is less than 5–10% or more 
90–95% (i.e. after myeloablative conditioning) and 
in other cases STR-PCR should be chosen.
MATRIX METALLOPROTEINASES 2 AND 
9 ACTIVITY AND TUMOR-ASSOCIATED 
MACROPHAGES IN HUMAN GASTRIC 
CANCER: CORRELATION WITH METASTASIS
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Introduction: Matrix metalloproteinases-2 and 
9 (MMP-2 and -9) participate in the degradation 
of extracellular matrix (ECM) in tumor that results 
in the invasion, neoangiogenesis and metastasis. 
It is also known that tumor-associated macrophages 
(TAM) are important source of MMPs. Aim: To study 
the interrelationship between TAM number (CD68-
positive cells) and concentration of MMP-2 and 
-9 active forms in tumor tissue as well as their link 
with clinicopathologic characteristics, metastasis into 
lymph node (LN) and survival of patients with gastric 
cancer (GC). Material and Methods: 112 resected 
specimens of primary gastric cancer were used. 
CD68 (tumor-associated macrophages) expression 
was evaluated using immunohistochemistry, and 
MMP-2 and MMP-9 activity, zymography. Statistical 
analysis was conducted using Spearmans’s test, 
Kaplan — Meier survival analysis, log-rank test and 
Cox proportional hazards model. All patients were 
thoroughly informed about the study, which was ap-
proved by the local Ethics Committee. Results: It was 
shown that TAM number in GC categorized as N1–2 and 
M1 was significantly higher than that in GC categorized 
as N0 and M0 (p < 0.05). Correlation of concentration 
of MMPs active forms in GC categorized as N0 and 
N1–2 was not statistically significant. At the same 
time MMP-2 activity was higher by 1.5-fold in tu-
mors categorized as N1 in comparison with those 
in tumors categorized as N0 (p < 0.05). Moreover, 
the inverse correlation between tumor concentration 
of MMP-2 active form and M category was shown: 
concentration of MMP-2 active form in tumor was 
higher by 2-fold in patients without distant metas-
tasis (p < 0.05). The positive correlation between 
TAM number and tumor concentration of active 
form of both MMP-2 and MMP-9 was observed 
(rho = 0.4 and rho = 0.51, respectively; p < 0.05). 
Overall survival (OS) of patients with concentration 
of active form of MMP-2 (< 2 μg/g) was signifi-
cantly better than that in patients with higher activity 
of MMP-2 in tumor (p=0.004). It was also shown that 
risk of unfavorable outcome increased by more than 
a factor of 3.5 (hazard ratio 3.8, (95% CI 0.78–8.2; 
p < 0.05) in patients with high concentration of ac-
tive MMP-2 in tumor. OS of patients with concentra-
tion of active form of MMP-9 (< 4.5 μg/g) was also 
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significantly better than that in patients with higher 
activity of MMP-9 in tumor (p=0.015). Hazard ratio 
for patients with MMP-9 activity of tumor > 4.5 μg/g 
(HR 4.7, 95% CI 0.83–7.7; p<0.05) was significantly 
higher than that for patients with MMP-9 activity 
< 4.5 μg/g. The survival rate of patients with high 
number of TAM in tumor tissue (number of CD68-
positive cells > 23%) was significantly lower than 
that of those with a low TAM number (p = 0.003). 
Risk of unfavorable outcome in patients with TAM 
number higher than the median value (> 23%) in-
creased by more than a factor of 2 (HR=2.4; 95% 
CI 0.86–7.25; p < 0.05). Conclusion: It was sug-
gested that TAM number and concentration of active 
form of MMP-2 and MMP-9 in gastric cancer may 
be used to the disease prognosis.
GENE EXPRESSION OF ACTIVATING 
TRANSCRIPTION FACTOR 5 AS A PREDICTOR 
OF SURVIVAL IN GERMINAL CELL DIFFUSE 
LARGE B-CELL LYMPHOMA
A. Martynchyk, I. Kriachok
National Cancer Institute, Kyiv, Ukraine
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Introduction: Prognostic models based on cur-
rently used methods of prediction of the outcome 
in diffuse large B-cell lymphoma (DLBCL) do not 
identify the molecular basis of clinical heterogeneity. 
Aim: To identify new independent predictor of survival 
in germinal B-cell like subtype (GCB) of DLBCL. Pa-
tients and Methods: Analysis was performed on RAW 
data from 203 DLBCL samples from a previously 
stu died cohort of patients treated with CHOP (Se-
ries 11318) using Partek Genomics Suite software 
(methods of regression analysis and Cox-model for 
prognostic significance of studied parameters). Study 
was conducted according to bioethical standards 
of National Cancer Institute (Kyiv, Ukraine). Only 
GCB samples were choosing for the next analysis. 
According to the IPI score 71 GCB samples were 
divided into two groups: with “high” IPI (3–4 risk 
factors, 14 samples) and “low” IPI (0–2 risk factors, 
50 samples). Detection of differentially expressed 
genes was performed (IPI high vs low IPI). Gene list 
was created (fold changes < -1.3, > 1.3, p-value with 
FDR < 0.05). 37 differentially expressed genes were 
detected. Highest fold-change was in gene activating 
transcription factor 5 (ATF5). The medium expression 
of this gene in GCB subtype of DLBCL was 5.42 and 
the expression was higher in high IPI samples vs low 
IPI (7.5 vs. 4.9 respectively). GCB samples were di-
vided into two groups depending on APF5 expression. 
In Kaplan — Meier survival analysis the probability 
of survival was better for patients with low expression 
of ATF5 compared to high expression. Results: Higher 
expression of ATF5 was observed in patients from high 
risk group (IPI score 3–4) (p-value with FDR 0.05) 
and the proba bility of survival was less for this group 
of patients treated with CHOP, especially after one 
year of follow up. Conclusions: ATF5 could be a useful 
prognostic factor for DLBCL, but its significance need 
to be verified in further studies.
ABERRANT EXPRESSION OF IKZF1 GENE 
IN BLAST CELLS OF CHILDHOOD ACUTE 
LYMPHOBLASTIC LEUKEMIA
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Introduction: Modern molecular-genetic methods 
of acute lymphoblastic leukemia (ALL) research re-
vealed alterations of a number of novel genes involved 
in pathogenesis. The most frequent are transcription 
factors of lymphoid differentiation, such as pax5, 
EBF-1, IKZF1 (Ikaros), IKZF2 (Helios), IKZF3 (Aiolos). 
Ikaros, coded by IKZF1 gene, is a key factor of early 
lymphocyte development. Knock-out of IKZF1 leads 
to high frequency of lymphoid malignances and 
autoimmune disorders. The Ikaros protein contains 
4 DNA-binding zinc fingers forming DNA-binding do-
main near the N-terminus. The IKZF1 gene contains 
8 exons and is transcribed as at least 16 isoforms due 
to alternative splicing. Long isoforms (Ik1–3) have 
at least three zinc fingers, which are able to bind DNA 
and are considered to be functional. Short isoforms 
(Ik6,8,9,0) lack two or more zinc-finger domains and 
impair the function of Ikaros proteins in a dominant-
negative manner (DN-Ik). Aim: Estimation of Ikaros 
isoforms expression by RQ-PCR in bone marrow 
(BM) blast cells of primary and relapsed childhood 
ALL patients in comparison with mononuclear cells 
of healthy donors’ BM. Methods: We developed panel 
of primers and probes for independent quantitative as-
sessment of all isoforms expression. Deletion of exon 
3–6 was examined at the genomic level by PCR. Re-
sults: 132 BM samples from 104 ALL patients were 
analyzed, including 43 relapses and 27 paired cases. 
9 BM from healthy donors composed a control group. 
Profile of Ikaros expression was similar in controls and 
most patients. Levels of Ikx, Ik2, Ik4 and Ik8 isoforms 
were significantly lower in patients. In 18 (27.3%), 
3 (4.5%) and 1 (1.5%) out of 66 cases aberrant 
overexpression of Ik6, Ik9 and Ik0, respectively, was 
found. In 13 of 18 (72%) cases DN-Ik overexpression 
was detected in relapsed and primary patients who 
finally relapsed. Deletion in IKZF1 gene was found 
in 11 of 103 (10.7%) cases. In 24 cases both deletion 
and Ik-DN expression was absent, and in 4 both fea-
tures were present. In 9 cases Ik6 was overexpressed 
in the absence of deletion. Pair cases at diagnosis 
and relapse displayed the same Ikaros status. Con-
clusions: Expression of DN-Ik is a relatively frequent 
event for ALL. It may be detected by RQ-PCR analysis 
of cDNA apart from genomic analysis and possibly 
associated with poor prognosis. Ik6 expression 
may be caused not only by the exon 3–6 deletion 
in IKZF1 gene. Ik6 overexpression is hardly the factor 
of relapse, but rather it is an initial event at the time 
of de novo diagnosis.
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Introduction: Development of a new combination 
of antitumor remedies replacing one or two compo-
nents in well-known combinations by preparations with 
more selective antitumor activity is one of approaches 
to improve effectiveness of cancer pharmacotherapy. 
Aim: To create new combinations of antitumor drugs 
on a basis of initial combinations from standard treatment 
protocols for cancer replacing cyclophosphamide, fluo-
rouracil and bonefos by chlofiden, fludinat and mebifon, 
which were developed in SI “IPT NAMSU”. Materials 
and Methods: Toxicological and histological meth-
ods and method of tumor allografts were used. Mela-
noma B16 and Lewis lung carcinoma (3LL) were used 
as tumor models. Drugs were injected intraperitonially 
24 hours after tumor implantation. Drug dosage for mice 
based on single dose for human was calculated using 
rapid extrapolation method. Results: The substitution 
of phosphorylated chlorethylamine chlofiden and fludi-
nat for traditional combinations of cyclophosphamide 
and fluorouracil restored high antitumor activity of initial 
combinations but reduced their toxicity (chlofiden does 
not induce nephro- and hepatotoxicity, unlike cyclophos-
phamide; toxicity of fludinat is 3.3 fold lower than that 
of fluorouracyl). Thus, new remedies have more selec-
tive antitumor action. In melanoma B16, combination 
of doxorubicine, 3.0 mg/kg, cisplatine, 3.0 mg/kg and 
cyclophosphamide, 30.0 mg/kg, caused 80.5% of tumor 
growth inhibition, while replacement of cyclophospha-
mide by chlofiden, 30.0 mg/kg, in this combination 
enhanced tumor inhibition up to 85.9%. Doxorubicine, 
3.0 mg/kg, cyclophosphamide, 30.0 mg/kg and fluoro-
uracil, 37.0 mg/kg caused 90.2% of 3LL growth inhibition, 
meanwhile the same combination with fludinat, 37.0 mg/
kg, instead of fluorouracil showed 85.9% of 3LL growth 
inhibition. Toxicity of mebifon and bonefos is similar, but 
mebifon showed higher antitumor activity than bonefos 
(72.0% and 37.4% of B16 growth inhibition respectively). 
Combination of dacarbazine, 60.1 mg/kg, cisplatin, 
1.5 mg/kg, vinblastine, 0.2 mg/kg and bonefos, 14.0 mg/
kg inhibited growth of melanoma B16 by 81.7%, the 
substitution of mebifon, 14.0 mg/kg, for bonefos resulted 
in 91.6% of B16 growth inhibition (10% higher than initial 
combination). Conclusions: On the basis of combina-
tions from standard cancer treatment protocols of NCI 
of Ukraine, there were developed combinations of an-
ticancer remedies with replacement of cyclophospha-
mide, fluorouracil and bonefos by chlofiden, fludinat and 
mebifon. Combinations of chlofiden and fludinat had the 
same antitumor activity and were less toxic than standard 
combinations. The replacement of bonefos by mebifon 
enhanced antitumor activity of initial combination.
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Introduction: Influence of environmental factors 
plays a crucial role in the formation and development 
of cancer. The peculiarity of combined action of adverse 
factors on the human organism is the ability of each 
factor to modify the overall pathogenic effect. Nitro-
gen oxides (NOx) and low doses of ionizing radiation 
(LDIR) are genotoxic factors. Their interaction can lead 
to increased levels of DNA damage, changes in cell 
response to stressors, alterations in microenvironment 
of cells in tissues, the development of nitrosative and 
oxidative stress, resulting in increase of carcinogenic 
risk. At present, genotoxic effect of combined influ-
ence of environmental factors on organism upon tumor 
growth is studied insufficiently. In this regard, investiga-
tion of the antioxidant system status and the develop-
ment of genetic instability upon the tumor growth and 
combined action of exogenous NOx and LDIR is impor-
tant. Aim: To investigate changes in DNA damage and 
dynamics of the activity of superoxide dismutase (SOD) 
and catalase (CAT) in the process of tumor growth 
in the conditions of the individual and combined effect 
of exogenous NO and LDIR. Methods: The formation 
of DNA strand breaks was determined using horizontal 
gel electrophoresis of isolated rat’s peripheral blood 
lymphocytes (PBL). The object of study were PBL of rats 
exposed to NO inhalation (150 mg/m3 of air) for 30 days 
and LDIR (10-fold by 0.1 Gy) in the conditions of indi-
vidual and combined treatment. Changes in CAT and 
SOD activity in rat peripheral blood were investigated 
in parallel. Guerin carcinoma (GC) was used as a tu-
mor model. Study was approved by Ethical Committee 
permission of IEPOR NASU (Kyiv, Ukraine). Results: 
GC growth was accompanied by decrease of CAT ac-
tivity in the blood of rats after 12 days of tumor growth. 
CAT activity increased both upon single LDIR and joint 
influence of NO+LDIR and reached its maximum upon 
combined action. The activity of SOD in blood increased 
in the conditions of the action of LDIR and NO+LDIR, 
and also upon the GC development. GC inoculation 
after treatment with NO+LDIR significantly increased 
the SOD activity on the 12 day followed by normalization 
on the 18 day of tumor growth. However, the increased 
activity of antioxidant enzymes was insufficient in the 
conditions of oxidative and nitrosative stress. Individual 
action of NO and LDIR resulted in DNA damage gradual 
increase during tumor growth. Maximal genotoxic effect 
was observed in the case of NO and LDIR combination 
(4-fold excess of the control value). Conclusions: Pre-
liminary impact of NO and/or LDIR resulted in persistant 
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additive genotoxic effect accompanied by the increase 
of genetic damage on background of GC growth after 
the direct action of these factors. Tumor development 
and combined effect of environmental factors of differ-
ent nature were accompanied by complex interactions 
between the main enzymes of antioxidant protection — 
CAT and SOD. An imbalance of free radical processes 
under oxidative and nitrosative stresses lead to the 
development of genetic instability, which in turn is a fac-
tor of increased carcinogenic risk and implemented 
as accelerated tumor growth
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Introduction: In recent years the incidence 
of colorectal cancer (CRC) is significantly increased 
in all countries, including Ukraine. The problem is CRC 
metastasis in the liver at the time of diagnosis in 25–30% 
of patients. Aim: To improve the efficiency of treatment 
of CRC patients with liver metastases using drugs of 
“ERBISOL” class (Kyiv, Ukraine). Patients and Meth-
ods: The study included 111 CRC patients with liver 
metastases at the disease stage T1–4N0–2M1. All pa-
tients underwent surgical treatment. The patients were 
divided into 2 groups: group 1 (control, 54 patients) who 
underwent treatment by Roswell-Park scheme; group 
2 (57 patients), which, on chemotherapy Roswell-Park 
scheme held 18 cycles of treatment with Erbisol Ultra-
pharm.. The study protocol was approved by Ethical 
committee. Results: According to preliminary research, 
Erbisol Ultrapharm is a metabolic antimutagen, its use 
helped to reduce the number of multiaberrant and an-
euploid cells, also Erbisol Ultrapharm exhibits properties 
of natural cytostatic agent that inhibits the abnormal cell 
growth. The analysis of the clinical course of the disease 
showed that in patients of group 2 general condition has 
been improved without local and general side events, 
and allergic reactions. In group 2, stabilization of the 
disease occurred in almost half of cases, compared with 
control patients where the progression of the disease was 
recorded in two thirds of patients. Additional biotherapy 
with Erbisol showed improvement in clinical response and 
duration of stable disease (13.5 months ± 1.0 in the main 
group, 7.4 ± 1.1 months in the control group, p <0.05); 
and the median duration of effect (13.3 ± 1.0 months 
in the main group, 7.0 ± 1.1 months in the control group, 
p < 0.05). The trend for improved clinical effect was 
observed in patient survival rate. Conclusion: The use 
of drugs of “Erbisol” class in the combined treatment 
of CRC patients is a new and promising approach improv-
ing treatment effectiveness. Combined therapy of CRC 
patients with liver metastases using 5-FU and drugs of 
“Erbisol” class prolongs duration of disease stabilization 
and increases patient survival (p < 0.05).
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Introduction: Screening of single nucleotide poly-
morphisms (SNP) allows determining the genetic pre-
disposition to various multifactorial diseases and may 
help to predict individual sensitivity to pharmacological 
agents. Aim: To conduct clinical-genealogic, molecu-
lar-genetic studies in patients with ovarian cancer (OC) 
and / or breast cancer (BC), benign tumor of the female 
reproductive system from the families with cancer his-
tory. Patients and Methods: The clinical-genealogic 
study of 45 patients aged 25–72 years was carried out. 
19 (42.2%) patients had cancer of the female repro-
ductive organs (OC, BC, stage I-II), 26 (57.8%) — be-
nign tumor of the uterus, ovary and breast. The genetic 
analysis was used to identify BRCA1 (185delAG and 
5382insC) and BRCA2 (6174delT) genes mutations 
and ESR1 (T-397C, A-351G), Cyp2D6*4 (G1846A) 
genes polymorphism in peripheral blood DNA of the 
patients. Results: Among 19 OC and BC patients with 
familial cancer 5382insC mutation in BRCA1 gene 
was detected in 2 (10.5%) patients. Other mutations 
in BRCA1/2 genes were not found. The -397C allele 
(CC and CT genotypes) of ESR1 gene was detected 
with the same frequency in patients with cancer and 
benign tumor, respectively, 50.0 and 45.7% (p > 0.05). 
The frequency of -351G allele (GG and AG genotypes) 
of ESR1 gene was significantly higher in cancer 
patients compared to patients with benign tumor, 
respectively, 71.4 and 25.7% (p < 0.05). However, 
the frequency of 1846A allele (GA and AA genotypes) 
of Cyp2D6*4 gene was significantly higher in women 
with benign tumor than in cancer patients, respectively, 
17.1% and 0.05% (p < 0.05). Among cancer patients 
we found more individuals (13–68.4%) with combi-
nation of two polymorphisms in investigated genes 
in comparison with benign tumor patients (12–46.2%). 
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Conclusion: Analysis of BRCA1/2 genes mutations 
and polymorphic variants of ESR1 gene among healthy 
patients with familial cancer can be useful tool for ge-
netic risk estimation of cancer development.
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Introduction: Cancer cell-specific aberrantly 
methylated DNA was found in blood plasma from 
cancer patients, indicating that cell-free DNA cir-
culating in blood (cirDNA) is a convenient source 
of tumor-associated DNA markers for the minimally 
invasive diagnostic tests. Aim: Estimation of the di-
agnostic and prognostic significance of methylation 
changes in RARB2, RASSF1A tumor suppressor genes 
detected in the cirDNA from lung cancer patients 
before and after combined treatment. Methods: 
Blood samples were taken from 33 healthy subjects 
(HS) and 60 patients with non-small cell lung can-
cer (NSCLC) before treatment, after neoadjuvant 
chemotherapy, surgery and during post-treatment 
follow-up. CirDNA was extracted from blood plasma 
and cell-surface-bound cirDNA (csb-cirDNA) fraction 
which was obtained by successive treatment of blood 
cells with PBS/EDTA and trypsin solutions. Concentra-
tion of methylated and unmethylated RASSF1A and 
RARB2 tumor suppressor genes circulating in blood 
was quantified by methylation-specific PCR and meth-
ylation index (IM) was calculated as IM = 100 х [copy 
number of methylated /(copy number of methylated 
+ unmethylated gene)] for plasma cirDNA and csb-
cirDNA. Results: Methylation index for RASSF1A, 
RARB2 genes was elevated 2–3 fold in plasma cirDNA 
and csb-cirDNA from lung cancer patients versus 
HS (Mann — Whitney U-test, p<0.05). Exceeding 
of at least one of RASSF1A or RARB2 IM values over 
the selected cut-offs discriminates NSCLC patients 
from healthy subjects with 90% sensitivity and 82% 
specificity when plasma cirDNA and csb-cirDNA 
were analyzed. The mean RARВ2 IM in csb-cirDNA 
was higher for stage III patients compared with stage 
I–II patients (p < 0.05). In post-surgery period most 
patients had more pronounced decrease of RASSF1A, 
RARB2 IM in both plasma cirDNA and csb-cirDNA 
compared with IM values detected before treat-
ment and after chemotherapy. The increased level 
of methylation markers was found in blood of patients 
with recurrent NSCLC after treatment. Conclusions: 
Detection of RARB2, RASSF1A methylation changes 
in csb-cirDNA and plasma cirDNA of NSCLC patients’ 
blood appeared to be more informative in comparison 
with analysis of plasma cirDNA only. The obtained data 
provides evidence that RARB2, RASSF1A IM analysis 
in the cirDNA is valuable for lung cancer diagnostics, 
evaluation of cancer treatment efficiency and post-
treatment monitoring.
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OF RADIATION-INDUCED DAMAGE 
IN GENETIC APPARATUS OF HUMAN CELLS
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Introduction: Accumulation of chromosomal 
aberrations in cells is potentially oncogenic; thus, 
ionizing radiation (IR), which induces such changes, 
is a carcinogenic factor. Combination of chemical 
agents, IR with different mechanisms of action on hu-
man genome still has to be elucidated. Aim: To deter-
mine and provide a comparative analysis of combined 
action of irradiation, co-mutagens, and mutagens 
using cell culture of human peripheral blood lym-
phocytes (LPB). Materials and Methods: Culture 
of LPB, metaphase chromosomes cytogenetic analy-
sis after ionizing radiation in the range of 0.3–2.0 Gy; 
co-mutagen verapamil (V) treatment in different con-
centrations (1.5–4.0 μg/ml); mutagen — nitrozotiol 
(GSNO) treatment as a transport form of nitrogen 
oxide (0.25–1.0 mM/ml) (experiments in vitro, 
two cell generations after irradiation). Results: 
A phenomenon of co-mutagenesis, which stands for 
combined action of radiation exposure (0.3–2.0 Gy) 
and V treatment (1.5–4.0 μg/ml of blood), on the 
level of chromosomal aberrations in PBL has been 
established. It has been shown that V at concentra-
tion of 4.0 μg per ml of blood increased the damag-
ing effect of low doses of radiation up to 1.5-fold. 
Frequency of chromosomal aberrations (radiation 
markers) became higher with the increase of concen-
tration of co-mutagen V (1.5–4.0 μg/ml). Combined 
treatment of PBL with IR and mutagen GSNO (two 
cell generations after irradiation) resulted in syn-
ergistic effect which enhanced the additive effect 
due to chromosomal aberrations, which are known 
to be the genetic markers of chemical agents’ action. 
Proliferative potential of PBL decreased more than 
60% under IR and GSNO treatment. Level of aberra-
tions of the chromatid type rose with increasing con-
centrations of GSNO (0.5 mM to 1.0 mM) by 3-fold. 
Combination of low doses of radiation and V inhibited 
cell proliferative potential, but increasing of exposure 
dose did not alter this effect. Conclusions: Increase 
in concentration of co-mutagens in combination with 
ionized radiation enhances chromosomal aberra-
tions in PBL. Moreover, proliferative potential of PBL 
decreases under IR and GSNO treatment. Low doses 
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of radiation and V inhibit cell proliferative potential; 
nevertheless, it remained unchanged when the doses 
of radiation were increased.
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Introduction: Peritoneal recurrence is a major 
cause of surgical treatment failure in patients with 
colorectal cancer (CRC). Diffuse metachronous 
peritoneal carcinomatosis is associated with poor 
prognosis and median survival of 5–6 months. There 
is a chance for prolongation of survival in patients 
with limited peritoneal carcinomatosis who are eli-
gible for aggressive combined treatment. Evaluation 
of peritoneal relapse risk at a time of surgery for pri-
mary colorectal tumor is essential for early diagnosis 
and treatment of metastasis. The presence of free 
cancerous cells (FCC) within the peritoneal cavity 
is believed to be a powerful predictor of peritoneal 
carcinomatosis. A method of real-time polymerase 
chain reaction (PCR) was proposed recently to detect 
FCC in peritoneal washes. Aim: To evaluate the feasi-
bility of real-time PCR for detection of FCC within the 
peritoneal cavity of patients with CRC who underwent 
curative surgery and to compare the results with those 
of conventional cytology. Patients and Methods: 
Twenty-two patients were enrolled in this study with 
ethical considerations. Patients were divided into 
three groups. The main group consisted of 16 patients 
radically operated for CRC. Positive control group 
included three patients with macroscopic peritoneal 
carcinomatosis diagnosed at a time of surgery for 
CRC. Negative control group consisted of three pa-
tients with benign colorectal tumors. A laparotomy 
and subsequent peritoneal lavage were performed 
in all 22 patients. Peritoneal wash samples were ana-
lyzed microscopically by Giemsa staining and by PCR 
analysis with primers for carcinoembryonic antigen 
(CEA) gene as a molecular target of cancerous cells. 
Real-time thermal cycler “Bio-Rad iCycler iQ5” (USA), 
PCR reagent kits “Fermentas” (Lithuania) and oligo-
nucleotide primers “Metabion” (Germany) were used. 
Cases with CEA signal were defined as PCR-positive. 
Results: PCR reaction was positive in three (19%) 
of 16 patients in the main group, while cytology was 
negative in all samples. No positive results of PCR 
and cytology in negative control group was detected, 
i.e. both methods yielded no false-positive results. 
Cytological examination was positive only in one 
(33%) of three patients of positive control group 
showing lack of sensitivity, whereas all (100%) of them 
were PCR-positive. Conclusions: CEA identification 
by PCR appears to be reliable method of FCC detec-
tion. It can be useful for identifying patients at high 
risk of peritoneal relapses of colon cancer following 
primary tumor resection. PCR is a more sensitive 
method for FCC detection in peritoneal washes com-
pared to conventional cytology.
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Introduction: Multiple myeloma (MM) is plasma 
cell neoplasm with different sensitivity to drug treat-
ment. The drug resistance worsens the individual 
prognosis for MM patients. Aim: To determine the 
predictive markers of refractory forms in MM pa-
tients. Methods: 130 patients with first time diag-
nosed ММ from different regions of Ukraine were 
examined during the period of 2007–2011. 26 (20%) 
of 130 patients underwent treatment according 
to the scheme МР, 55 (42.31%) — according to the 
scheme М2, 49 (37.69%) — according to the scheme 
VAD. Patients were divided into two groups: the 1st 
group — 52 patients, who had no response to treat-
ment, the 2nd group — 78 patients with response 
to treatment. Patients of both groups were scruti-
nized closely with a help of 68 clinical-laboratory 
indexes and molecular-genetic tests, and GSTT1, 
GSTM1 genes deletion polymorphism, GSTP1 gene 
А313G polymorphism, MDR1 gene C3435T polymor-
phism were characterized. Binary logistic regression 
with consequent including of predictors (program 
SPSS 16.0) was implemented to create a predictive 
model. Results: The patients of the 1st group had 
significantly lower frequency of GSTM1 gene dele-
tion polymorphism as compared to patients of the 2nd 
group (32.20% and 62.82%, respectively; χ2 = 11.33, 
OR = 0.29 (0.14–0.60), p < 0.001). The GSTM1 gene 
allele polymorphism correlated with elevated risk 
of development of refractory forms in MM patients 
(OR = 3.48 (1.66–7.29)). There was no difference 
in the frequency of others genes polymorphism. 
We have found that the higher prognostic value had 
GSTM1 gene polymorphism (69.90%), while calcium 
and α2-globulin level in blood serum before treatment 
had lower prognostic value (62.30%). The better 
prognostic value was obtained using statistical model 
which includes GSTM1 gene polymorphism, α2-
globulin and calcium levels in blood serum (73.60%). 
Conclusion: Implementation of predictive model 
which considers GSTM1 polymorphism, α2-globulin 
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and calcium levels in blood serum from the beginning 
of treatment increases the accuracy of prognosis 
of response to treatment for each individual patient.
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Introduction:  Molecules of cell adhesion 
(CD44 and E-cagherin) are significant for tumor 
growth and are connected to changes of cell prolif-
eration and migration. Recently, it was hypothesized 
that cancer stem cells (CSCs) express CD44 which 
regulates cancer cell survival, metastatic potential, 
resistance to conventional radio-chemotherapy, 
disease relapse and prognosis. Aim: To evaluate 
the interrelations of CD44 and E-cadherin expres-
sion with clinical and cytomorphological features 
of serous ovarian cancer and its clinical significance. 
Patients and Methods: Immunohistochemical and 
morphological of CD44 and E-cadherin expres-
sion analysis was applied to pathological material 
obtained after surgery of 72 patients with ovarian 
cancer of I-III stage (FIGO classification) before 
neoadjuvant chemotherapy. Monoclonal antibod-
ies against СD44 (clone DF 1485) and E-cagherin 
(clone NCH-38) were used. Results of immunohis-
tochemical analysis were evaluated by semi-quan-
titative assessment, the percentage of CD44 (+) 
and presence/absence of E-cadherin (+) cells were 
estimated. Survival of patients was analyzed by Ka-
plan — Mayer method. Results: Variability in the 
number, distribution, and location of CD44 (+) and 
E-cadherin (+) tumor cells was observed in ovarian 
cancer patients. Expression of CD44 was defined 
in solid structures, and also in clusters of tumor 
cells (budding) located in stroma, in cells of tumor 
papilles, in adenomatous structures, and in gland 
lumen which in total provides the evidence of cel-
lular discohesion and active invasion. The expres-
sion of CD44 (+) (over 10%) was observed in 58.3% 
patients. The negative correlation between CD44 (+) 
and E-cadherin (-) expression was determined 
(r = -0.38 p < 0.05). Survival analysis of ovarian can-
cer patients showed that 5-year survival of patients 
with tumor phenotype СD44 (+), Е-cadherin (-) was 
lower compared to survival of patients with tumor 
phenotype СD44 (-), Е-cadherin (+). Conclusion: 
In serous ovarian cancer variability of СD44 and 
E-cadherin expression was determined. СD44 ex-
pression in zones of cellular discohesion and active 
invasion of tumor cells was shown. We demonstrated 
the correlation between the percentage of CD44 (+) 
cells and survival of ovarian cancer patients. The 
results from this study suggest that quantification 
of CD44 (+) and E-cadherin (-) expression and their 
localization in ovarian cancer can be helpful as pre-
dictors of tumor progression.
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Introduction: Breast cancer (BC) is a leading 
cause of cancer death among women. In most cases, 
death results from the dissemination of cancer cells 
and the development of distant metastases. Approxi-
mately 65–75% of patients with advanced breast 
cancer will develop bone metastases, which result 
in bone destruction. The presence of disseminated 
tumor cells (DTC) in bone marrow (BM) of BC pa-
tients has been proven to have clinical relevance. 
Despite the clinical significance of DTCs in the BM, 
the biological relevance remains controversial. 
Microenvironment plays an important role in tumor 
progression both within primary tumor and distant 
metastases in secondary sites. BM is a depot of vari-
ous growth factors. It is not excluded that increased 
level of some cytokines may serve as the additional 
factor of prediction progression of tumor growth, 
because certain cytokines create the microenviron-
mental conditions for the establishment of distant 
metastases from a primary BC. Therefore, a search 
of new comprehensive prognostic algorithm, based 
on simultaneous detection of DTC in BM and cytokine 
profile in BC patients, should promote the develop-
ment of personalized therapeutic approaches. Aim: 
The aim of this study was to detect DTC in BM and 
determine an impact of cytokine status of peripheral 
blood (PB) and BM of primary BC patients to can-
cer prognosis. Methods: Immunocytochemistry, 
bioassay tests, ELISA, cultivation tests and statisti-
cal methods. Results: In our study DTC in samples 
of BM was revealed in 50% breast cancer patients 
of progression group. The level of TNF, CSF-1, IL-6, 
TGF-β1, VEGF and IFN was analysed. It was found 
that most significant additional markers of tumor pro-
gression with detection of DTC in BM are the levels 
of TNF in BM and PB, of CSF-1 and IL-6 in PB and 
of endogenous IFN in BM and PB of BC patients. 
In patients of disease progression group in com-
parison with patients in remission group the levels 
of TNF in BM were increased by 44% (p < 0.01), 
of CSF-1 and IL-6 in PB — by more than on 40–60% 
(p < 0.05). Conclusion: Comprehensive detection 
of DTC in BM and identification of the levels of TNF, 
IFN, CSF-1, VEGF, IL-6 and TGF- β1 in PB and 
BM of BC patients could be one of the ways to predict 
metastatic process and correct antitumor individual-
ized therapy.
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Introduction: Design of new strategies for breast 
cancer (BC) treatment is still one of the actual prob-
lems in oncology. The main phase of complex therapy 
of locally disseminated BC stage II–III is neoadjuvant 
chemotherapy. Nowadays different prognostic values 
are being used in clinical practice, but objective criteria 
of BC sensitivity to neoadjuvant chemotherapy, which 
could give data about answer to chemotherapy on or-
ganism and tumor levels, are still unclear. Aim: To study 
connections between ferritin levels in serum and tumor 
tissue with sensitivity to neoadjuvant chemotherapy 
in BC patients. Patients and Methods: We studied 
168 women with BC stage IIА–IIIB. Age of patients ranged 
from 28 to 69 years. Serum ferritin was measured by solid-
phase immunoenzyme assay after histological verifica-
tion of diagnosis before the first cycle of neoadjuvant 
chemotherapy. Patients received FAC, AC chemotherapy 
(2–6 cycles) every 21 days. Neoadjuvant chemotherapy 
efficacy was evaluated every 2 cycles by mammography 
according to RECIST criteria. Ferritin expression studies 
were performed on operation material of BC patients 
by standard immunohistochemical assay with specific 
monoclonal antibodies. Statistical analysis was performed 
using STATISTICA 6.0 software. Results: Patients were 
divided into 2 groups according to the degree of the 
clinical effect after neoadjuvant chemotherapy. The first 
group consisted of 79 BC patients with positive reaction 
on chemotherapy: complete tumor regression was ob-
served in 8, partial — in 71 patients from this group. The 
second group consisted of 89 women with tumors resis-
tant to chemotherapy. Among them 61 patients showed 
stabilization of tumor growth and 28 — tumor progression 
after neoadjuvant chemotherapy. The highest levels of se-
rum and tumor ferritin were registered in group of patients 
with tumors resistant to neoadjuvant chemotherapy. 
In particular at the beginning of the therapy before the first 
cycle of neoadjuvant treatment average ferritin concen-
tration in serum of these patients was 226.2 ± 5.7 ng/ml 
(213.4 ± 4.8 ng/ml — in patients with stabilization and 
254.2 ±6.2 ng/ml — in patients with progression of tumor 
growth). At the end of treatment patients with resistant 
tumors showed significant (p < 0.05) elevation of serum 
ferritin levels (to 294.7 ± 7.3 ng/ml in patients with stabi-
lization and to 351.9 ± 5.5 ng/ml — in patients with tumor 
progression). Most part (87%) of tumors from the resistant 
group of patients showed elevated levels of ferritin expres-
sion in operation material. The highest levels of expres-
sion of this protein (more then 92% of positive cells) was 
observed in tumors with progression after neoadjuvant 
treatment. Patients with tumors sensitive to neoadjuvant 
therapy had slightly elevated average concentration 
of serum ferritin before the first cycle of neoadjuvant che-
motherapy (93.1 ± 2.8 ng/ml: 56.8 ± 4.0 ng/ml in patients 
with full and 97.2 ± 3.1 ng/ml in patients with partial tumor 
regression). After treatment patients with sensitive tumors 
showed significantly (p < 0.05) lower serum ferritin levels 
(4.3 and 3.2 times for patients with full and partial tumor 
regression, respectively). Average and low levels of fer-
ritin expression were observed only in 18% of tumors with 
partial regression, although tumors with full regression 
showed absence of this protein expression. Correla-
tion analysis showed reverse correlation between levels 
of serum and tumor ferritin and sensitivity of BC patients 
to FAC and AC neoadjuvant chemotherapy (r = -0.39; 
p < 0.05). Conclusions: So, we found relations between 
levels of ferritinin in serum and tumor tissue with sensitivity 
to neoadjuvant chemotherapy of BC patients. High serum 
and tumor ferritin levels point on resistance of BC patients 
to neoadjuvant chemotherapy. The acquired data showed 
that ferritin level should be used as objective criteria for 
determination of BC sensitivity to neoadjuvant chemo-
therapy on both organism and tumor levels.
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Introduction: It is well known, that properties 
of nanomaterial strongly depend on particle shape 
and size. Gold nanospheres have already become 
an object for targeted drug delivery research. How-
ever, recently more attention is drawn to nanoparticles 
with different geometrical parameters, particularly 
nanoprisms. Such nanocarriers can be successfully 
applied as delivery agents for photodynamic therapy 
(PDT). One of the most questionable aspects of this 
approach is nanoparticle interaction with different 
cell types. Aim: To assess the gold nanoprism toxic-
ity and ability to accumulate in malignant and normal 
cells in vitro and to evaluate the effectiveness of PDT 
in vivo using Fotolon-nanoprism composite as a pho-
tosensitizer. Methods: Human glioblastoma cell line 
A172 (kindly provided by Dr. S.P. Sydorenko), human 
Burkitt’s lymphoma cell line Namalwa, peritoneal 
mouse macrophages, normal human monocytes and 
lymphocytes were used for studies in vitro. Mice 
C57Bl/6 with transplanted Lewis lung carcinoma were 
used in PDT experiments. Nanoprisms with average 
diameter of 88.3 nm (determined by DLS analyzer 
«Analysette 12 DynaSizer”, «Fritsch”, Germany) were 
stabilized with chlorella polysaccharides. Chlorine e6-
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based drug Fotolon (RUE Belmedpreparaty, Belarus) 
was used as a photosensitizer. Accumulation of nano-
prisms in target cells was studied using dark-field 
microscopy. Cell viability in toxicity tests was assessed 
by trypan blue dye exclusion method. In vivo effective-
ness of gold nanoprisms was studied by assessment 
of tumor growth inhibition. Results: Cultured cells 
were incubated with nanoprisms at concentrations 
of 10 or 100 μg/ml for 1 hour in accumulation stud-
ies and 1 or 24 hours in toxicity stu dies. Dark-field 
microscopy studies of Namalwa cells showed that the 
nanoparticles accumulate mostly on the cell surface. 
Apparently, they do not penetrate cell membrane. 
Normal human lymphocytes do not accumulate 
nanoprisms even at concentration 100 μg/ml. On the 
contrary, treatment of peritoneal mouse macrophages 
and human blood monocytes, as well as human 
glioblastoma cells A172 with gold nanoprisms leads 
to nanoprism accumulation in cytoplasm. Gold nano-
prisms were not toxic to normal human lymphocytes 
in both concentrations tested (10 and 100 μg/ml). 
As to Namalwa cell line, viability of the cells, treated 
with nanoprisms, decreased slightly (by 6–8%) only 
after their incubation with maximal nanoparticle 
concentration. Evaluation of Fotolon-nanoprism 
composite activity in PDT tests in vivo showed inhibi-
tion of Lewis lung carcinoma growth to 70% versus 
32% in the group of animals treated with free Foto-
lon. Conclusions: 1. Gold nanoprisms are relatively 
nontoxic to cells. 2. Nanoprisms aggregated on the 
surface of transformed lymphocytes and did not ag-
gregate on the surface of normal cells. 3. The nanopar-
ticles were absorbed mostly by phagocytic cells. 4. 
Antitumor photodynamic activity of Fotolon-nanoprism 
composite exceeded such of the free Fotolon more 
than twice.
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Introduction: The immunogenetic study has dis-
closed the correlation between HLA alleles and diseas-
es. Investigated alleles could be used as genetic mark-
ers in the diagnosis of malignant diseases. However, 
the results of an immunogenetic research obtained 
in any population can not be automatically transferred 
to other ethnic groups. The HLA-distribution specific-
ity analysis in acute leukemia patients is of primary 
importance. This information can help practitioners 
to reveal individuals with a high probability of ma-
lignant diseases. Aim: The HLA-genotype analysis 
in children suffering from acute leukemia and in chil-
dren with non-malignant diseases. Marker specificy 
detection of high and low risk of leukemia progres-
sion. Methods: 25 children with acute lymphoblastic 
leukemia (ALL), 16 children with acute myeloblastic 
leukemia (AML) and 16 children with non-malignant 
diseases were included in the study. HLA-genotyping 
of leucocytes was performed by PCR-SSO (sequence 
specific oligonucleotide) and PCR-SSP (sequence 
specific primers) with reagent kits (Invitrogen, USA). 
The significance of discrepancy between groups was 
assessed by using chi-squared test. Results: The 
distribution pattern of HLA-alleles in two subgroups 
of patients with acute leukemia has been analyzed. The 
most frequent alleles in ALL patients were A*02 (15 pa-
tients, 34%), A*24 (9 patients, 18%), B*35 (9 patients, 
18%), B*07 (6 patients, 12%), C*07 (9 patients, 20%), 
C*04 (6 patients, 12%), DRB1*01 (9 patients, 18%), 
DRB1*04 (8 patients, 16%), DQB1*05 (11 patients, 
50%), DQB1*03 (15 patients, 36%). The most fre-
quent alleles in AML patients were A*02 (8 patients, 
34%), A*24 (4 patients, 16%), B*35 (5 patients, 
16%), B*51 (3 patients, 13%), C*07 (6 patients, 22%), 
C*06 (6 patients, 22%), DRB1*07 (6 patients, 22%), 
DRB1*11 (5 patients, 19%), DQB1*03 (7 patients, 
30%), DQB1*02 (7 patients, 27%). In patients with 
non-malignant diseases HLA-alleles distribution was 
the following: A*02 (8 patients, 31%), A*03 (5 patients, 
19%), B*44 (8 patients, 28%), B*08 (4 patients, 13%), 
C*07 (10 patients, 31%), C*04 (7 patients, 25%), 
DRB1*03 (5 patients, 19%), DRB1*15 (6 patients, 
19%), DQB1*02 (9 patients, 31%), DQB1*06 (9 pa-
tients, 28%). We displayed that differences between 
groups of ALL patients and patients with non-malignant 
diseases on НLА-DRB1*03 are statistically significant 
(p = 0.04). Conclusion: Analysis of HLA-DRB*03 locus 
has revealed the significant difference in ALL patients 
when compared with the group of children with non-
malignant diseases. Obtained results are of certain 
interest and require further investigation.
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Introduction: Photodynamic therapy (PDT) is a tu-
mor treatment modality, which is grounded on applica-
tion of a photosensitizing drug (PS) and light of appro-
priate wavelength which activates PS leading to tumor 
cell destruction. To enhance PDT antitumor effect, 
a number of approaches are now under investigation, 
including elaboration of targeting techniques, such 
as use of metal or polymeric nanoparticles, and de-
velopment of novel regimens of light and PS delivery. 
One of the promising approaches, which we exploited 
in this study, may be called metronomic or chronic 
PDT. It is based on continuous low level photoirra-
diation of a tumor and delivery of PS over extended 
period of time — from several hours to a few days. 
Aim: To establish a chronic regimen of PDT, provid-
ing controlled release and prolonged accumulation 
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of PS in tumors by employment of natural polymeric 
materials with simultaneous low-intensity light illumi-
nation, and to evaluate PDT effects on murine Lewis 
lung carcinoma (LLC) tumor growth and metastatic 
dissemination. Methods: C57Bl6 female mice (6 per 
qroup) with intracutaneous transplanted LLC were 
used. A special photodiode panel was developed 
for continuous low-intensity blue-light irradiation 
of tumor-bearing animals. Photosensitizer hemato-
porphyrin was loaded into 4% hyaluronic acid hydrogel 
which was inoculated intratumorally twice: on the 1st 
and 3rd days of light treatment. On the whole, mice were 
illuminated for 6 days. Before the start of experiments, 
kinetics of hematoporphyrin release from hyaluronic 
acid gel, introduced to mice, was determined by re-
cording its fluorescence in tumors for 5 days using 
USB 4000 fiber optic spectrometer (“Ocean Optics”, 
USA). All procedures involving animals were performed 
in accordance with the Institutional Animal Care and 
Use Committee. Results: Hyaluronic acid hydrogel 
during three days provided controlled release and 
higher accumulation (up to 7 times) of hematoporphy-
rin compared to free hematoporphyrin. This enabled 
us to use the gel-carrier for controlled release of hema-
toporphyrin in PDT experiments. For accomplishment 
of this chronic PDT, six-day illumination of LLC-bearing 
mice with hematoporhyrin-containing hydrogel was 
carried out. Remarkable inhibition up to 80% of tumor 
growth was observed in a group of treated animals 
compared to untreated ones. Moreover, the number 
of lung metastases in treated animals was 24-fold 
lower than in control group, indicating clear antimeta-
static effect of chronic PDT. Conclusion: A feasibility 
of controlled continuous release of hematoporphyrin 
photosensitizer from hyaluronic acid hydrogel was 
demonstrated. Six-day blue-light low-level illumination 
of tumors concomitant to controlled hematoporphyrin 
release resulted in remarkable antitumor and antimeta-
static effect, indicating significance of this approach 
to PDT of tumors.
THE PROGNOSTIC VALUE OF LEUKEMIC 
STEM CELLS PERCENTAGE IN B-LINEAGE 
CHILDHOOD ACUTE LYMPHOBLASTIC 
LEUKEMIA
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One generally accepted theory is that leukemia 
is maintained by leukemia stem cells (LSCs), which 
play the central role in drug resistance and metasta-
sis. It would be of great interest to study the quantity 
of LSCs during follow-up and their prognostic impact 
on different types of leukemia. Moreover, developing 
LSCs-targeted therapy may provide, in combination 
with standard therapy, a way to eradicate the leuke-
mic process. The aim of our study was to evaluate 
LSCs percentage and their prognostic meaning for 
childhood B-precursor acute lymphoblastic leukemia. 
Patients and Methods: We investigated cord blood 
samples from 87 children with B-ALL. The percentage 
of LSCs with phenotype CD34+CD38-CD19+ (Wil-
son K., 2010) in the blast population was determined 
at diagnosis. Minimal residual disease (MRD) was 
assessed by detection of aberrant immunophenotype 
using flow cytometry (FC 500, “Beckman-Coulter”). 
Comparisons of patient’s characteristics were per-
formed using the Mann — Whitney U-test. Data were 
presented as median and percentiles (25–75) and ac-
cepted as reliable at p < 0.05. Results: We observed 
that initial increased level of CD34+CD38-CD19+ cells 
correlates with a poor response to induction chemo-
therapy. The median content of CD34+CD38-CD19+ 
was 0.13% (0.01–3.7) for MRD-negative (<0.01% 
of blasts) and 2.1% (0.2–5.7) for MRD-positive 
(> 0.01% of blasts) patients at 15th day of induction 
chemotherapy (p <0.05). We compared the proportion 
of the LSCs within the blast population in both diag-
nostic groups at day 36 and found that MRD-positive 
patients have higher content of LSC at diagnosis than 
MRD-negative: 3.3% (1.4–5.7) and 0.6% (0.06–3.7) 
respectively (p < 0.05). Conclusion: Thus, increased 
LSCs percentage correlates significantly with a lack 
of complete response in patients with childhood B-
ALL. CD34+CD38-CD19+ compartment at diagnosis 
was higher for MRD-positive patients at 15 and 36 days 
of chemotherapy. The prognostic impact of the MRD 
stem cell quantity might improve the already strong im-
pact of total MRD quantity on outcome. Identification 
of new therapeutic targets based on LSCs biological 
features is the aim of the future studies.
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Introduction: In ovarian cancer (OC) patients 
endometrial pathology is diagnosed, that is explained 
by the common risk factors and pathogenesis of the 
diseases. The aim: To study the relationship be-
tween general and recurrence-free survival rate 
in OC patients and presence/absence of associated 
endometrial hyperplasia (EH). Patients and Meth-
ods: Retrospective analysis of history of diseases 
in 303 OC patients with stages I-IV who underwent 
standard treatment according to the radical program 
in National Cancer Institute within 2001–2008 years. 
The study protocol was approved by Ethical Committee 
permission of National Cancer Institute (Kyiv, Ukraine). 
Results: Group of OC patients with EH composed 
59.1% (among those — reproductive age patients 
made up 46.9%, menopausal period patients — 
53.1%), without EH — 40.9% (among those — repro-
ductive age patients made up 30.5%, menopausal 
period patients — 69.5%). The morphology of ovarian 
tumor of patients with associated EH were allocated 
as follows: papillary adenocarcinoma — 69.8%, 
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stromal tumors — 11.2%, mucinous cancer — 6.1%, 
germinogenic tumors — 3.3%, non-differentiated ad-
enocarcinoma — 1.7%, endometrioid cancer — 1.1%. 
Correlation relationship of general and recurrence-free 
survival rates was defined in the investigated patients 
due to presence or absence of associated EH. It was 
shown that the median of recurrence-free survival 
of OC patients with EH made up 60 months, while 
in absence of EH — 24 months (p < 0.05). The five-
year survival rate in OC patients with EH composed 
53%, in absence of EH — 32% (p < 0.05). It is worth 
to note that early recurrences of the disease (pro-
longatio morbi) was observed in 24% of OC patients 
in presence of EH and in 76% patients with its absence 
(p < 0.05). Conclusions: Thus, the presence of benign 
endometrial changes is a favorable prognostic sign 
that is associated with OC prognosis. The obtained 
data have practical significance as predictive factors 
for estimation of OC prognosis.
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Introduction: The protein c-Jun belongs to the 
subgroup of DNA binding transcription factors that 
form AP-1 dimers. c-Jun is unique in its ability to posi-
tively regulate cell proliferation through the repression 
of tumor suppressor gene expression and function, 
and induction of cyclin D1 transcription. c-Jun is phos-
phorylated on Ser63 and Ser73 following activation 
of signalling cascades, which made c-Jun maximally 
effective in stimulating transcription. However, the 
exact role of c-Jun in gastric oncogenesis is un-
known. Aim: To determine the phosphorylated form 
of c-Jun content in the lysate of rat gastric mucosa 
cells in chemically induced gastric cancer develop-
ment. Methods: The content of phospho-c-Jun was 
measured by Sandwich ELISA method using the assay 
kit PathScan Phospho-c-Jun (Ser63) (Cell Signaling 
Technology, USA) and represented in conventional 
unit of absorbancy on mg of the protein. The protein 
concentration was registered by Bradford’s method. 
Gastric carcinogenesis was initiated by 10-week 
replacement of drinking water by 0.01% solution 
of carcinogen N-methyl-N’-nitro-N-nitrosoguanidine 
(MNNG), at the same time the rats were redefined 
on diet containing 5% NaCl. The samplings of mate-
rial were performed at the end of 4th, 6th, 8th, 10th, 12th, 
18th and 24th week. The study protocol was approved 
by Ethical Committee permission of Educational and 
Scientific Center “Institute of Biology” (Kyiv, Ukraine). 
Results: At the end of the 4th week of MNNG and NaCl 
consumption the control reference of phospho-c-Jun 
content was observed. The gastric mucosa cells were 
characterized by increased content of phospho-c-
Jun at 4 and 6.3 fold over the control at the end of 6th 
and 8th weeks, respectively, of the of MNNG and NaCl 
treatment. Also it was established that the MNNG and 
NaCl treatment for 10 weeks causes 1.9-fold increase 
in phospho-c-Jun content compared to the control. 
At terminal stages (12, 18 and 24 weeks) of the gas-
tric carcinogenesis study there was a stable increase 
of phospho-c-Jun content on the average at 3.6-fold 
in comparison with reference values. Conclusions: 
The increased level of the phosphorylated form 
of c-Jun from 6th to 24th week of gastric cancer devel-
opment was probably caused by activation of MAP-
kinase cascade and inactivation of phosphatases 
that would lead to the intensification of target genes 
transcription responsible for cell proliferation.
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Introduction: Global development of wireless 
technologies, including cellular telephony and Wi-
Fi, leads to a tremendous growth of radiofrequency 
electromagnetic radiation (RF-EMR) level in human 
environment. Today some studies revealed both epi-
demiological and experimental evidence on potential 
carcinogenicity of long-term exposure to the low 
intensity RF-EMR from the modern wireless devices. 
Aim: To demonstrate the effectiveness of epidemio-
logical approach (a public survey) as well as the model 
biological experiments in RF-EMR risk assessment. 
Materials and Methods: 1) We interviewed stu-
dents of Kyiv region on a specificity of cellular phones 
use and self-assessment of their health, including 
a headache, an earache, and a physical discomfort 
manifestation. 2) We used a model of Japanese quail 
embryos in ovo for the assessment of metabolic 
changes in living cells under the low intensity RF-EMR 
exposure. Results: The survey of Ukrainian students 
(17–21 years old) revealed that about a half of them 
used cellular phones for talking more than 1 h per 
day, and about 25% of them — more than 2 h per day. 
And 42% of students surveyed had a headache and/
or an earache during the long-term cellular-phone 
conversations. A strong correlation between headache 
prevalence and the duration of everyday cell-phone 
conversations was revealed. We could not exclude 
at least partial effect of RF-EMR from the cellular 
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phones in the phenomena revealed. On the other hand, 
the exposure of quail embryos in ovo to extremely low 
intensity RF-EMR of GSM 900 MHz standard during 
at least 158 h led to significantly increased levels of su-
peroxide and nitrogen oxide, TBA-reactive substances 
and 8-oxo-dG in embryo cells. This was accompanied 
by a depression of antioxidant enzymes activity in the 
cells. Previously the distinctive mutagenic effects 
of this regimen of RF-EMR exposure on the quail em-
bryos were demonstrated by alkaline comet assay. 
Conclusions: Both epidemiological and experimental 
approaches used in this study were effective in the risk 
assessment of the low intensity RF-EMR. Our findings 
indicate the necessity of at least wide implementa-
tion of the precautionary principle as for uncontrolled 
exposure of the public to RF-EMR from the modern 
wireless devices.
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Introduction: More than 60% of advanced 
pancreatic cancer (APC) patients suffer from 
resistant pain syndrome whether they were previ-
ously resected or not. One of effective and minimal 
invasive pain control techniques is paravertebral 
neurolytic block (PNB). The most frequent adverse 
effect of PNB is postneurolytic pain (PP) persist-
ing up to 7 days and more after the procedure. 
Aim: To decrease PP in the patients after PNB and 
to study the effectiveness of PNB in combination 
with prolonged ropivacaine epidural infusion (PREI) 
in APC patients. Patients and Methods: Group 
I consisted of 21 sequential patients matched 
to inclusion criteria and treated by PNB in our clinic 
before we have started PREI application in postneu-
rolytic period. Group II consisted of 21 sequential 
patients matched to inclusion criteria and treated 
with PNB and PREI. Neural roots were identified 
at Th5–Th10 level by rhythmic eliciting paresthesia 
and/or pain radiating to corresponding body seg-
ment according to frequency of Stimuplex® DIG elec-
trostimulation after puncture. 0.2% ropivacaine was 
used for PREI. Numeric Pain Rating Scale (NPRS) 
from 0 to 10 and morphine equivalent dose (MED) 
for tramadol daily intake were used for evaluation 
of pain. The study protocol was approved by Ethi-
cal Committee permission of Bogomolets National 
Medical University (Kyiv, Ukraine). Results: Pain 
assessment in postneurolytic period is represented 
in Table. Average duration of PREI application was 
6.4 ± 1.3 days. 14 patients from group I and 11 pa-
tients from group II completely refused opioids. 
No severe side effects of PREI as pronounced 
arterial hypotension or paresis of lower extremities 
were recorded.
Table. Pain assessment in patients with advanced pancreatic cancer.
Pa-
tients
Initial level Day 3rd after PNB Day 7th after PNB
NPRS MED NPRS MED NPRS MED
Group I 7.11±0.23 38.20±0.90 8.44±1.21 54.60±5.30 4.85±0.86 15.70±2.40
Group II 6.98±0.29 39.10±1.20 3.73±0.45 12.40±0.80 3.96±0.58 14.90±1.90
p value >0.05 >0.05 <0.05 <0.05 >0.05 >0.05
Conclusion: PREI application significantly reduces 
PP in early postneurolytic period. PNB in combination 
with PREI is effective and safe technique to reduce pain 
and improve quality of life in APC patients.
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Introduction: One of the main problems of oncolo-
gy is the low efficiency of treatment against dissemi-
nated forms of neoplastic process — recurrence and 
metastasis, which is the main cause of high mortality 
among cancer patients. The important characteristic 
of disseminated cancer is the presence of tumor cells 
in the bone marrow (BM), as in many cases the use 
of high-dose chemotherapy by accepted protocols 
is inefficient. The goal was to prevent cancer progres-
sion and bone metastasis in breast cancer patients 
with disseminated tumor cells (DTC) in BM and with 
elevated levels of TNF in BM using modified schemes 
of polychemotherapy with bisphosphonates. Pa-
tients and Methods: This research was carried out 
during the therapy of 119 patients with breast cancer 
in a disease stage T1–4N1–2M0. DTCs and TNF were 
analyzed in BM of all patients before therapy. The 
patients with DTCs in BM were divided into 2 groups. 
Group 1 (n = 20) underwent preoperative therapy 
according to AC (doxorubicin + cyclophosphamide) 
scheme. Group 2 (n = 27) received preoperative ther-
apy in compliance with AC — Paclitaxel scheme and + 
Zoledronic acid (Zometa) in the postoperative period. 
Patients with high level (more than 150 pg/ml, n = 53) 
TNF in BM were divided into the same two therapeu-
tic groups (n = 27 and n = 26). Results: It was found 
that DTC had been present in 47 patients (39.4%). 
Proportion of patients who were in 36 months remis-
sion was about the same in both groups — with DTC 
in BM or without it (59.5% and 60.2% respectively). 
The efficacy of treatment schemes AC → P + Zometa 
schemes vs. 48.9% in AC group. A similar pattern 
is evident while comparing the same therapeutic pat-
terns for patients with high level of TNF in BM. Disease 
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progression was observed in 25.9% of patients with 
AC → P + Zometa schemes vs. 73.1% in AC group. 
Conclusion: Presence of DTC and TNF in the bone 
marrow indicates a high risk of disease progression for 
patients with breast cancer. Preoperative polychemo-
therapy according to the scheme of AC → P followed 
by Zometa in the postoperative period for patients with 
DTC in BM and high TNF levels in BM is more effective 
in comparison with AC scheme.
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Introduction: Recent studies show that Trigonella 
foenum graecum (Leguminosae family), commonly 
known as fenugreek, has growth-inhibiting activ-
ity against some kinds of experimental tumors. Aim: 
To study the effect of fenugreek on lifespan of tumor 
bearing animals. Materials and Methods: Experi-
ments were carried out on the adult C57Bl/6 female 
mice with subcutaneously grafted Ca755 mammary 
carcinoma, and adult C57Bl/6 male and female mice 
transplanted with Lewis lung carcinoma (3LL). The 
animals in the experimental group were administered 
with the mix of fenugreek powder (250 mg/kg of body 
weight) and standard mash from the day of tumor graft-
ing up to the end of experiments. All experiments were 
carried out according to the rules of local Ethic Com-
mittee and were approved by the Ethic Board of IEPOR 
NASU. Results: The fenugreek consumption increased 
the lifetime of Ca755 carcinoma mice by 19%, and 
3LL-bearing male and female mice by 9% and 26%, 
respectively. Moreover, it was shown that fenugreek 
consumption has resulted in the inhibition of Ca755 ad-
enocarcinoma growth by 48%. Anti-metastatic effect 
of mentioned agent was also observed: an average 
volume of the metastases per animal was decreased 
by 86% and 18% in the female and male mice, re-
spectively. Conclusions: The results have shown that 
fenugreek can be considered a potential anticancer 
agent with more significant effect in the female animals.
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